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EVALUATION OF TREATMENTS FOR CORONARY ARTERY DISEASE  
UTILIZING CONTEMPORARY STATISTICAL METHODS 
 
Lauren Ji-Yon Kim, PhD 
University of Pittsburgh, 2006 
 
Cardiovascular disease is the leading cause of mortality worldwide, and approximately half of all 
cardiovascular deaths are attributed specifically to coronary artery disease (CAD).  Coronary artery 
bypass grafting (CABG) and percutaneous coronary intervention (PCI) procedures play a prominent role 
in managing the heavy burden of CAD.  The purpose of this dissertation was to evaluate revascularization 
treatment in patients with multivessel coronary disease.  Specifically, predictors of long-term prognosis 
and factors related to selection of revascularization strategy were investigated in the BARI and BARI 2D 
cohorts, respectively. 
 In BARI, treatment with CABG was associated with a significantly lower risk of sudden cardiac 
death, but did not impact any other causes of mortality.  Moreover, protection conferred by CABG was 
observed in patients regardless of diabetes status.   
 Following successful initial PCI in BARI, male gender, proximal LAD disease, and incomplete 
revascularization were associated with an increased risk of a first subsequent revascularization event but 
not latter events.  Diabetes and extensive CAD, on the other hand, demonstrated an incremental impact on 
the number of repeat procedures over 10 years of follow-up. 
 Among patients with diabetes and stable CAD in BARI 2D, angiographic features associated with 
the extent and location of coronary disease greatly influenced the decision to perform CABG over PCI.  
Geographic region, independent of patient characteristics, was also a driving factor in treatment selection, 
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with a greater propensity to recommend PCI in the US.  In all countries of origin, we observed substantial 
variation across individual clinical sites in this decision-making process.   
 Results in the BARI cohort may have clinical implications on guiding initial revascularization 
strategy and underscore the importance of intensive management of atherosclerotic risk factors in order to 
limit disease progression.  Our investigation of BARI 2D demonstrate the need for rigorous evaluation of 
optimal CAD treatment approaches in diabetic patients and factors that guide this decision-making 
process in current practice.  Overall, these findings may be useful for devising long-term treatment 
strategies that address the chronic, progressive, and systemic nature of coronary disease, which will be of 
great public health importance as medical advances continue to extend the lives of individuals with CAD. 
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1.0  DISSERTATION OVERVIEW AND OBJECTIVE 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, and approximately half of all 
cardiovascular deaths are attributed specifically to coronary artery disease (CAD).  Myocardial 
revascularization has a prominent role in managing the heavy burden of ischemic heart disease and an 
increasing number of these procedures are performed each year.  Given the chronic and progressive 
nature of atherosclerosis, long-term outcomes following coronary intervention are of great interest.  On 
the other hand, evolution of therapy, PCI in particular, requires continual reassessment of treatment 
strategies and the factors related to their use. 
 The purpose of this dissertation is to evaluate coronary revascularization treatments in patients 
with multivessel disease utilizing contemporary statistical methods.  Specifically, the following questions 
are addressed in a series of three research papers: 
 
1.   In patients with treated diabetes, revascularization with CABG (versus balloon-only PCI) has 
been shown to significantly increase long-term survival in the BARI trial, by conferring 
protection against cardiac death.  Although a modest survival benefit of CABG has been reported 
in the overall coronary revascularization patient population, this finding has been less consistent 
across clinical trials.  What is the impact of treatment with CABG on specific causes of death?  
Does CABG have a differential effect on cause-specific mortality? 
 
2.   A recognized limitation of percutaneous intervention is the need for additional revascularization 
procedures, which pose an increasing economic and health burden on individual patients as well 
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as health care systems.  Among patients who undergo successful initial PCI, what factors are 
associated with the need for additional revascularization treatments?  Do these predictors have a 
different effect on the number of repeat procedures?   
 
3.   Advances in PCI technology and adjunctive therapies over the last decade have markedly lowered 
rates of short-term complications and restenosis.  As a result, percutaneous interventions are 
increasingly used to treat select high-risk subsets of patients who have traditionally undergone 
bypass surgery.  In contemporary practice, what factors influence the selection of CABG over 
PCI in patients with diabetes and stable coronary disease?  Do practice patterns vary across 
geographic regions? 
 
 Research questions for the first and second papers were evaluated in the Bypass Angioplasty 
Revascularization Investigation (BARI), which compared an initial revascularization strategy of CABG 
versus balloon PCI in patients with multivessel disease.  Research questions for the third paper were 
examined in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, which 
was designed to simultaneously compare diabetes and CAD treatment strategies in patients with diabetes 
and stable coronary disease.   
  2
2.0  BACKGROUND 
2.1 CARDIOVASCULAR DISEASE 
2.1.1 Epidemiology of Cardiovascular Disease 
Cardiovascular disease (CVD) is the leading cause of death in nearly every region of the world according 
to the World Health Organization, accounting for an estimated 30% of all mortality.1  In sub-Saharan 
Africa, the sole exception, CVD is expected to surpass infectious disease, the current leading cause of 
death in this region, within the next decade.  A marked rise in the burden of CVD is anticipated globally, 
as the proportion of cardiovascular deaths is projected to increase from 29% in 1990 to 36% in 2020.2  
The detrimental impact of cardiovascular disease is far-reaching, and the notion that atherosclerosis is a 
disease of affluent, industrialized countries is no longer accurate.   
 In the United States, cardiovascular disease affects an estimated 71.3 million individuals.3  As the 
leading cause of mortality in both men and women, 37% of all deaths in 2003 were attributed to CVD.4  
Coronary artery disease (CAD) comprises half of all cardiovascular events, including death, among adults 
under 75 years of age.5  According to the National Health and Nutrition Examination Survey (NHANES 
1999-2002), an estimated 53% of all cardiovascular mortality was due specifically to CAD, followed by 
18% for stroke.6   
 The economic burden of cardiovascular disease further demonstrates the scope of CVD as a 
major public health problem.  In 2006, the direct and indirect cost of CVD is estimated at $403.1 billion, 
of which $142.5 billion is for CAD alone.5  In a rating of the most costly medical conditions in the US, 
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ischemic heart disease, the uncontested leader, was associated with an 8% increase in total healthcare 
spending between 1987 and 2000.   
 Despite an increasing prevalence of CAD, mortality from coronary heart disease in the US has 
actually declined in recent decades.3, 7, 8   From 1968 to 1981, age-adjusted CAD mortality decreased at a 
rate averaging 3% per year.8 A steady decrease in stroke deaths during this period resulted in substantial 
reduction in death rates from major cardiovascular and all causes, which was observed in all regions of 
the country.  According to more current estimates from the Framingham Heart Study, a 59% decrease in 
CAD mortality was reported between 1950 and 1999.4  The sizable and sustained decline in CHD and 
CVD mortality have been attributed largely to improved management of cardiovascular risk factors and 
progress in the diagnosis and treatment of coronary disease over the last 3 decades.9, 10 
 As medical advances lead to increased longevity, the elderly will comprise a growing proportion 
of the general population.  According to the US Census Bureau, approximately 40 million Americans will 
be over the age of 65 by 2010, which represents a dramatic demographic shift that has been underway 
since the 1950s.6  Aging of the population is expected to be a driving factor in the escalating health and 
economic burden of cardiovascular disease for years to come. 
2.1.2 Risk Factors for Cardiovascular Disease 
Extensive epidemiologic research has led to identification of cardiovascular risk factors.  Determinants 
with proven causality include: high low-density-lipoprotein (LDL) and low high-density-lipoprotein 
(HDL) levels, type 2 diabetes (which is related to hyperglycemia and hyperinsulemia), hypertension, 
cigarette smoking, and obesity.11-13  In recent years, studies carried out simultaneously in basic science 
laboratories have identified a number of new candidate risk factors, including elevated levels of 
prothrombotic factors (e.g. fibrinogen and PAI-1), inflammatory markers (e.g. C-reactive protein), 
homocysteine, and lipoprotein(a).14, 15  Although causation has not yet been established between these 
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emerging risk factors and cardiovascular disease, there is mounting evidence of a real cause-and-effect 
relationship.14-17 
2.1.3 Pathophysiology of Coronary Artery Disease 
CAD generally refers to the pathological condition in which atherosclerotic progression in the coronary 
arteries restricts blood flow to the myocardium.  Early pathogenesis is characterized by endothelial 
dysfunction, vascular inflammation, and build-up of lipids, calcium, and cellular debris in the intimal 
lining of the vessel wall.18, 19  During positive remodeling, fibrous plaque deposits outside of the lumen 
and extends outward, allowing the diameter of the lumen to be maintained.  With progression of 
atherosclerosis, the plaque mass extends into the lumen, decreasing its diameter and obstructing blood 
flow through the coronary arteries.20  Endothelial erosion or rupture of the fibrous cap can cause plaques 
to become ‘vulnerable’ and encroached in the vessel wall.18, 19  Vulnerable plaques may not be 
obstructive, and therefore remain undetected until they rupture and become clinically apparent.  Severe 
narrowing of the coronary arteries and rupture of vulnerable plaques ultimately lead to restricted blood 
flow, and thus, inadequate oxygenation of the myocardium.   
2.2 DIABETES AND CORONARY HEART DISEASE 
2.2.1 Epidemiology of Diabetes and Coronary Disease 
Type 2 diabetes is an established and powerful predictor of coronary disease that has evolved into a major 
public health concern in recent years.  Diabetes affects more than 150 million adults worldwide, and 
prevalence is expected to reach 300 million by 2025.21  The rising burden of diabetes is even more 
alarming in the US where prevalence is currently estimated at 17 million,22 representing a more than 2-
fold increase over the last decade.23, 24  The total economic burden of diabetes was estimated at $98 billion 
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in 2003, accounting for approximately 1 of every 10 dollars allocated to health care.  More than half of 
this expenditure covered indirect costs (i.e. temporary or permanent disability and premature deaths), and 
nearly one-fifth of the direct medical costs was for management of cardiovascular complications.5   
 Epidemiological studies have played an important role in elucidating the relationship between 
diabetes and cardiovascular disease.  Diabetic individuals typically have an increased number of 
atherogenic risk factors including hyperglycemia, insulin resistance, hypertension, dyslipidemia, heart 
failure, autonomic dysfunction, peripheral vascular disease, cerebrovascular disease, microvascular 
disease, a prothrombotic state, and nephropathy.25, 26  Diabetes has been associated with a 2- to 3-fold 
increase in the risk of cardiovascular disease in the Framingham Study 27 and a 2- to 4-fold increase in the 
risk of developing ischemic heart disease in the Atherosclerosis Risk in Communities (ARIC) study.28  
Moreover, individuals with diabetes manifest symptoms earlier in life and more severely compared to 
those without diabetes.  In fact, it has been reported that diabetic patients without a history of MI have a 
similar likelihood of experiencing an MI as non-diabetic patients with a prior MI, emphasizing the 
importance of aggressive treatment of CVD risk factors in diabetic patients regardless of MI history.29  
More than 80% of the diabetic population ultimately die as a result of CVD.26  The Multiple Risk Factor 
Intervention Trial (MRFIT) reported that the absolute risk of cardiovascular mortality among men was 3-
times higher in diabetics compared to non-diabetics.  Even after adjusting for effects of age, race, income, 
blood pressure, cholesterol level, and smoking, diabetes remained a potent predictor of cardiovascular 
disease.30 
 Recently, the NHANES cohort was examined to determine whether diabetic individuals benefited 
from the decline in CAD mortality observed in the US population in recent decades.31  Between the early 
1970s and 1980s, non-diabetic men experienced a 36% decline in age-adjusted CAD mortality compared 
with only a 13% decline in those with diabetes.  During the same period, the age-adjusted CAD death rate 
among women decreased 27% in non-diabetic but increased 23% in diabetic women.  Based on their 
findings, the NHANES researchers concluded that improvements in treatment of CVD (which resulted in 
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marked decline in CAD mortality in the overall population) appeared to be less effective in individuals 
with diabetes, particularly women.   
2.2.2 Pathophysiologic and Anatomical Features of CAD in Diabetes 
Unique pathophysiologic and anatomical features of coronary disease in diabetic patients contribute to 
their worse prognosis.  Hyperglycemia is believed to play a central role in atherosclerotic progression by 
contributing to endothelial cell dysfunction, which inhibits vasodilation and increases vascular smooth-
muscle proliferation, thrombogenesis, and proatherogenic cellular processes.32  Enhanced platelet 
aggregation mediated by increased expression of glycoprotein (Gp) IIb/IIIa receptors further contributes 
to endothelial cell dysfunction, accelerated disease progression, and coronary thrombosis.33  Individuals 
with diabetes have elevated levels of fibrinogen,34 coagulation factor VII,35 and von Willebrand factor.36  
These haemostatic abnormalities lead to a prothrombotic state which likely contributes to the problem of 
restenosis in diabetic patients.  Dyslipidemia also plays a role in pathogenesis of CVD via glycosylation 
of LDL particles which stimulate smooth muscle cell migration and proliferation.37 These are some of the 
biological and metabolic abnormalities that are thought to promote restenosis and accelerate disease 
progression in persons with diabetes. 
 Diabetic individuals typically bear a greater atherosclerotic burden that is characterized by 
multivessel disease,38, 39 obstructions in left main coronary artery,40, 41 presence of diffuse lesions,42 more 
totally occluded segments,43  and lipid-rich plaques vulnerable to rupture.44  In addition, diabetic patients 
have an impaired ability to develop coronary collaterals45 and undergo favorable remodeling,46 which are 
two intrinsic mechanisms for alleviating the burden of atherosclerosis.  Taken together, these anatomic 
features explain, at least in part, the more frequent and severe occurrence of ischemic coronary events and 
a generally poor prognosis in patients with diabetes, particularly following cardiac intervention. 
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2.3 MYOCARDIAL REVASCULARIZATION FOR TREATMENT OF CAD 
Coronary revascularizations play a prominent role in managing the heavy burden of CAD and in 2003, an 
estimated 467,000 coronary artery bypass grafting (CABG) surgeries and 664,000 percutaneous coronary 
intervention (PCI) procedures were performed in the US.5  With mean costs exceeding $30,000 per 
CABG and $12,000 per PCI (including hospital and physician fees), the total direct cost for coronary 
revascularization in the US is more than $28 billion annually.47  Selection of the preferred strategy is 
often determined by the severity of disease and feasibility of PCI based on coronary anatomy and lesion 
morphology.  Other factors, such as patient’s age and comorbidities, may also play a role in selecting the 
more appropriate method of revascularization.48, 49 
2.3.1 Coronary Artery Bypass Grafting Surgery 
Approximately 10% of patients with coronary disease undergo CABG in the US,50 which is considered 
the standard approach for treatment of significant left main disease and multivessel disease, especially 
when the proximal left anterior descending (LAD) artery is involved.  During surgical revascularization, 
most of the epicardial vessel is bypassed, including symptom-causing culprit lesions and, more 
importantly, “future” culprit lesions which are thought to be responsible for most mid- and long-term 
coronary events.51  In this way, patients who are treated with CABG generally receive a more complete 
and durable revascularization, particularly when internal mammary artery (IMA) grafts are used, and 
therefore, less frequently need additional subsequent procedures.  These benefits, however, come at the 
cost of CABG being a major surgical procedure with attendant risks, including perioperative myocardial 
infarction (MI), stroke, and death, as well as potential complications of general anesthesia and 
cardiopulmonary bypass such as cognitive impairment.52  These factors translate into a longer 
hospitalization and overall recovery and higher initial cost, compared to percutaneous intervention.   
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2.3.2 Percutaneous Coronary Intervention 
In the US, approximately 1 in 3 patients with CAD undergo less invasive percutaneous coronary 
intervention which is directed at treating culprit lesions.50  For patients with extensive and diffuse 
coronary disease, or complex lesions that are not amenable to treatment with balloon angioplasty or 
stenting, PCI is a suboptimal strategy.  But for suitable candidates, PCI offers the advantages of lower 
periprocedural risk, shorter recovery, and lower initial cost.  However, since the focalized approach 
results in a less complete revascularization than bypass surgery, a major limitation of percutaneous 
intervention is the need for additional procedures to address restenosis (re-narrowing of lumen to >50% 
occlusion which occurs in 30% to 57% of patients after PCI)53-55 and atherosclerotic progression in native 
vessels.   
 For many years, these two revascularization strategies have been considered complementary, with 
the less invasive PCI generally well-suited for patients with limited lesions and CABG reserved for those 
with more severe and extensive coronary disease.  Advances in PCI technology and adjunctive therapy in 
the last decade have narrowed this gap, and as a result, indications for percutaneous intervention have 
expanded to include those who would have, historically, been treated with bypass surgery.  Drug-eluting 
stents have dramatically lowered incidence of restenosis,56 and use of Gp IIb/IIIa receptor inhibitors has 
improved short-term event rates.57, 58  Furthermore, refinements in PCI devices and techniques have 
enabled interventionalists to treat increasingly complex and severe lesions, leading to a drastic increase in 
the number of PCI performed each year.  In 2002, the number of PCI procedures performed in the US 
reportedly increased 326% over the previous 15 years.5  
2.3.3 Review of Randomized Trials Comparing CABG versus PCI 
Randomized controlled trials (RCTs) conducted in the past two decades provide considerable evidence 
regarding efficacy of CABG versus PCI procedures in the overall CAD patient population, and several of 
the more prominent trials are briefly introduced in this section.  Since these RCTs differ from each other 
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in terms of target study population, sample size, primary endpoint, and duration of follow-up,  this review 
is limited to randomized trials comparing CABG versus PCI (balloon-only and with stenting) in patients 
with multivessel coronary disease, who are the focus of this dissertation.   
2.3.3.1  CABG versus Balloon-Only PCI 
The Bypass Angioplasty Revascularization Investigation (BARI), the largest of these trials in the pre-stent 
era, was designed to compare an initial revascularization strategy of CABG versus balloon-only PCI in 
patients with multivessel disease amenable to treatment by both procedures.  The main finding in BARI 
was that mortality in the two treatment arms was not significantly different at 5 years (10.7% vs. 13.7%, 
respectively; P=0.19)59 and significantly lower in the CABG group at 7 years (15.6% in CABG vs. 19.1% 
in PCI; P=0.043).60  The Coronary Angioplasty versus Bypass Revascularization Investigation (CABRI)61 
and the Emory Angioplasty versus Surgery Trial (EAST),62 which both enrolled patients similar to BARI, 
reported that mortality was not significantly different following CABG versus PCI at 1- and 3- years, 
respectively.  Lack of a statistically significant difference in treatment effect was likely due, at least in 
part, to insufficient power arising from small sample size and relatively short follow-up periods.  In all 
three trials, patients treated with CABG consistently reported a significantly lower recurrence of anginal 
symptoms, and therefore, less frequent need for further revascularization.60-62  A meta-analysis which 
included these and several other randomized trials evaluating patients with multivessel coronary disease 
reported trend of a survival advantage of 2.3 percent at 5 years (P=0.03) and 3.4 percent at 8 years 
(P=0.03) conferred by CABG.63   
2.3.3.2  CABG versus PCI with Coronary Stents 
In recent years, CABG versus PCI randomized trials have incorporated the use of intracoronary stents as 
an adjunct to percutaneous intervention.  In the Arterial Revascularization Therapy Study (ARTS), the 
incidence of death, MI, or  stroke as a combined endpoint at 1- and 3-years of follow-up was not 
significantly different in patients assigned to CABG versus PCI with stenting;  however, 1-year event-free 
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survival was significantly higher among surgically treated patients (87.8% vs. 73.8%).64 The Stent or 
Surgery (SoS) trial also reported comparable rates of death or MI in the two treatment arms at 2 years 
(P=0.80).65  In contrast, the Argentine Randomized Study: Coronary Angioplasty with Stenting versus 
Coronary Bypass Surgery in Patients with Multivessel Disease (ERACI II) trial reported significantly 
lower 1.5-year rates for death (3.1% vs. 7.5%, P<0.017) and MI (2.3% vs. 6.6%, P<0.017) in the PCI 
versus CABG groups, respectively.66  Consistent with RCTs conducted in the pre-stent era, all three trials 
reported significantly higher rate of repeat revascularization following PCI compared to CABG (ARTS: 
16.8% vs. 3.5%;  SoS: 21% vs. 6%;  ERACI II: 16.8% vs. 4.8%;  all P<0.01).   
2.3.4 Coronary Revascularization in Patients with Diabetes 
Diabetic individuals account for an increasing proportion of patients undergoing coronary 
revascularization.  Of the estimated 1.5 million revascularization procedures performed each year in the 
US,67 approximately 25% are in diabetic patients who experience worse short- and long-term outcomes 
after both CABG and PCI, compared to those without diabetes.68-70  In particular, diabetic patients have a 
significantly higher risk of long-term mortality following coronary revascularization.71 
 An unexpected finding in BARI was that among patients with treated diabetes, a 15% absolute 
survival advantage was associated with CABG versus balloon PCI (P=0.003).59, 60  Moreover, improved 
survival in the CABG arm was attributed specifically to a reduction in cardiac deaths and was limited to 
patients who received at least one IMA graft.  Subgroup analyses of diabetic patients in the EAST and 
CABRI trials also suggested trend of improved long-term survival following CABG (vs. PCI); however, 
results were not statistically significant in either trial due to smaller sample sizes resulting in less 
statistical power to detect treatment differences.  Meta-analyses of these trials in the diabetes subset 
revealed a trend toward reduction in mortality following revascularization with CABG versus balloon-
only PCI at 4 years (P<0.01) but not at 6.5 years (P=0.71).63   
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2.3.5 Bypass Angioplasty Revascularization Investigation 2 Diabetes 
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) is a currently ongoing trial 
based on the results of BARI regarding treatment of coronary disease in patients with diabetes.  Using a 
2x2 factorial design, patients with diabetes and stable coronary disease were randomly assigned to 
intensive medical therapy alone versus intensive medical therapy plus immediate coronary 
revascularization for treatment of CAD;  and an insulin-sensitizing versus an insulin-providing strategy 
for diabetes management.72  Although treatment strategy for coronary disease was dictated by random 
assignment, selection of the mode of revascularization among patients randomized to the invasive 
intervention arm was at the discretion of treating physicians.  BARI 2D is expected to elucidate the 
optimal timing of coronary revascularization in patients with diabetes and stable CAD with respect to 
cardiac mortality.   
2.4 APPLICATION OF CONTEMPORARY STATISTICAL METHODS 
An appropriate and rigorous statistical analysis is an integral part of clinical research, and an important 
feature of this dissertation was the application of contemporary statistical methods to the BARI and BARI 
2D datasets.  This section introduces the three research papers at the heart of this dissertation and 
highlights the statistical procedure that was utilized in each. 
2.4.1 Multiple Failure-Time Analyses 
Extensions of traditional Cox proportional hazards regression were applied to model multiple competing 
outcome events in Research Paper 1 and recurrent events of the same type in Research Paper 2.  Figure 
2.1 illustrates how these multiple failure-time models differ from standard Cox regression and how they 
differ from each other. 
  12
 x EVENT
x 1stEVENT
2nd
EVENT
3rd
EVENT
x EVENT 2
EVENT 3
EVENT 1
a)    Cox Model
b)    WLW Model
c)    PWP Model
WLW indicates Wei-Lin-Weissfeld;  PWP Prentice-Williams-Peterson
  
Figure 2.1  Schematic diagram of three time-to-event regression models 
2.4.1.1  Modeling Multiple Competing Endpoints using WLW Regression 
In Research Paper 1, the impact of treatment with CABG on specific causes of long-term mortality was 
evaluated in the BARI cohort.  Four causes of death were modeled simultaneously using Wei-Lin-
Weissfeld (WLW) competing risks regression.73  Since causes of death are mutually exclusive competing 
outcomes, the occurrence of one event type removes the individual from being at risk for all other events.  
Therefore, patients were considered to be at risk for all four outcome events (or causes of death) until they 
either:  1) died, at which time the patient was considered to have had the ‘event’ for a specific cause of 
death and censored for the other 3 endpoints;  or 2) stopped being followed in the study, at which time the 
patient was censored for all 4 endpoints.   
 Fitting a single WLW model with four endpoints is, essentially, like fitting four separate Cox 
models, one for each defined endpoint.  A key advantage of WLW regression is that it allows multiple 
endpoints to be modeled simultaneously in the presence of competing risks, efficiently and without losing 
statistical precision.  In addition, having multiple endpoints in the same model allows for statistical tests 
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that would not be possible otherwise, such as testing whether the effect of a given predictor on each of the 
defined endpoints are significantly different from each other.   
2.4.1.2  Modeling Recurrent Events using PWP Regression 
In instances where patients experience multiple adverse events of the same type, analysis of the time-to-
first event is commonly undertaken using Kaplan-Meier74 and Cox proportional hazards regression75 
methods.  However, by ignoring the subsequent events, this approach does not make full use of the 
available data, and therefore, may not tell the full story of the treatment effect.    
 In Research Paper 2, predictors of repeat revascularizations after successful initial PCI were 
examined in the BARI cohort.  The number (or count) of subsequent procedures was modeled as a 
recurrent events outcome using methods described by Prentice, Williams, and Peterson (PWP).76  PWP 
‘conditional’ regression assumes that a patient cannot be at risk for a subsequent event until a prior event 
has occurred, and in effect, estimates the probability of having a subsequent revascularization event 
conditional on having experienced a prior event.  Interpretation of PWP models provides the following 
information:  In patients who undergo successful percutaneous intervention, what is the probability of a 
first subsequent revascularization event?  Among patients who received one additional procedure, what is 
the probability of a second repeat revascularization event?  And among those who received at least two 
subsequent procedures, what is the probability of a third event?     
2.4.2 Multilevel Modeling using GEE 
Multilevel models were first used by sociologists to examine how students’ educational achievement (a 
student-level endpoint) is influenced by factors such as the student’s race, class characteristics, and racial 
composition of the school (student-level and higher-level predictors).77  Similarly, multicenter studies also 
give rise to a hierarchical structure in the data, where patients are nested in clinical sites.  Data indicating 
that patients in the same clinical site tend to be more similar with respect to the outcome of interest 
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violates the assumption of independent observations, which is one of the most fundamental assumptions 
underlying traditional linear and logistic regression methods.  Ignoring correlation in the data leads to 
underestimated standard errors, and therefore, erroneously low p-values and narrow confidence intervals.  
Multilevel models take into account correlation in the data and provide correct parameter estimates. 
 In Research Paper 3, we evaluated what factors influence the selection of CABG over 
contemporary PCI in patients with diabetes and stable multivessel disease in the BARI 2D trial.  
Preliminary analyses indicated considerable correlation in the treatment selection outcome among patients 
clustered in clinical sites, and variable degrees of correlation between sites.  This led us to conclude that 
multilevel modeling using generalized estimating equations (GEE)78 which accounts for correlation 
within and between clinical sites would be the appropriate statistical procedure for multivariable analysis.   
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3.1 INTRODUCTION 
Cardiovascular disease is the leading cause of mortality in western countries.1  The specific causes of 
death vary and may be the result of sudden cardiac death, myocardial infarction (MI), and congestive 
heart failure (CHF).  Although the effect of coronary revascularization on all-cause and cardiac mortality 
has been previously described,2-5 there are limited data on the effect of revascularization on specific 
causes of death in patients with coronary artery disease (CAD).  Results from CASS6 and other studies7, 8 
indicate that revascularization with coronary artery bypass grafting (CABG) may impact specific causes 
of mortality, in particular sudden death.  Evaluation of cause of death may help elucidate the mechanism 
of disease processes and have important clinical implications for developing optimal treatment strategies 
to  improve long-term survival after coronary revascularization.   
 The Bypass Angioplasty Revascularization Investigation (BARI) study has data for cause-specific 
death in 3610 patients undergoing initial revascularization with either CABG or percutaneous 
transluminal coronary angioplasty (PTCA).2  The main finding in the BARI randomized trial was a 
significantly lower 7-year mortality in the CABG treatment arm compared to PTCA (16% and 19%, 
p=0.04).9  Among patients with treated diabetes at baseline, 7-year mortality was also significantly lower 
in those randomized to CABG versus PTCA (24% and 44%, p=0.001), which was attributed to a 
reduction in cardiac deaths.10  However, there was no treatment difference in mortality among patients 
without diabetes (14% in CABG vs. 13% in PTCA; p=0.72).  
 The purpose of this manuscript is to investigate the impact of revascularization with CABG on 
specific causes of mortality in the BARI cohort.   
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3.2 METHODS 
3.2.1 Study Design 
BARI was an IRB-approved, multicenter clinical trial designed to compare an initial revascularization 
strategy of CABG versus PTCA on long-term mortality in selected patients with multivessel coronary 
artery disease judged suitable for both procedures.  A detailed description of the study aims, eligibility 
criteria, and patient selection procedures has been published previously.11  In brief, symptomatic patients 
with multivessel CAD were randomly assigned to treatment with either CABG or PTCA and followed 
after revascularization.  Eligibility criteria included clinically severe angina or evidence of ischemia 
requiring revascularization and angiographically documented CAD involving 2 or 3 vessels amenable to 
revascularization by either CABG or PTCA.   
 Participants were enrolled from 18 clinical sites in the United States and Canada between August 
1988 and August 1991.  Of the 4107 eligible patients identified, 1829 patients gave written informed 
consent and were randomized to receive either CABG or PTCA.  Eligible patients who declined 
randomization were given the opportunity to participate in the BARI “Eligible Not Randomized” (ENR) 
registry, in which the patients and their physicians selected the initial treatment but had similar follow-up 
schedules as the randomized patients.  2010 patients gave informed consent to participate in the BARI 
ENR registry.  The BARI cohort of revascularized patients is the focus of this analysis, specifically, those 
who received their assigned revascularization treatment in the randomized trial and those who were 
revascularized within 3 months of enrollment in the registry. 
 Identical baseline data were collected for all patients, which include demographic descriptors, 
clinical history, 12-lead electrocardiogram (ECG), coronary angiography measurements, angina, 
functional status, medications, risk factors, and quality of life.  All ECGs were interpreted by a core 
laboratory.  Although angiograms were evaluated by a central laboratory for the randomized patients, 
only clinical site evaluations were obtained for the registry patients;  therefore, angiographic data based 
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on clinical site interpretation were used in this analysis.  In this analysis, CABG was defined as 
revascularization with CABG at any time during the BARI study.  Thus, patients who initially received 
PTCA, either by random assignment or by choice, and subsequently underwent CABG during follow-up 
are classified as having received CABG. 
 Follow-up data were obtained at 4 to 14 weeks and at 1, 3, and 5 years, and telephone contacts at 
6 months and at 2 and 4 years.  After 5 years, follow-up contacts were made annually by telephone, and 
vital status was obtained for 98% of the patients as of September 15, 1997.   
3.2.2 Classification of Cause-of-Death Outcomes 
Deaths were classified by an independent Mortality and Morbidity Classification Committee (MMCC) 
using the following documents, if available: death certificate; report from the clinical site’s principal 
investigator; coroner’s report; surgical and catheterization laboratory reports if death occurred within 30 
days of a coronary revascularization procedure; ECG and cardiac enzyme levels measured within 24 
hours of death; and in-hospital data ascertained from medical records.  Each death was reviewed 
independently by 2 members of the MMCC and classified into one of the following primary 
classifications: direct or contributory cardiac, atherosclerosis-related non-cardiac, non-cardiac medical 
(e.g. cancer, pulmonary disease), non-cardiac trauma, accident, suicide, and other, unknown, or 
unclassifiable causes.11  Disagreements between reviewers on the primary cause of death were resolved 
by full committee consensus.   
 Deaths determined to be of cardiac origin received one of the following secondary classifications: 
sudden death, death secondary to MI, CHF, cardiogenic shock, unwitnessed beyond 1 hour, and other 
documented cardiac causes.  Agreement between the 2 reviewers on the secondary classifications was not 
required in BARI, and thus 2 reviewers could assign different secondary causes to the same patient death.  
For patients with multiple secondary causes, the following hierarchy was applied in order to determine the 
cause of death classification to be used in this analysis: unwitnessed beyond 1 hour was preferred over MI 
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death which was preferred over sudden death which was preferred over CHF and finally over other 
cardiac causes.  Using these classifications, the following 4 endpoints were defined for this analysis:   
Sudden death includes deaths within 1 hour of the onset of cardiac symptoms and deaths 
unwitnessed beyond 1 hour. 
MI death includes deaths within 30 days of documented or probable MI, and deaths resulting 
from cardiogenic shock. 
CHF and other cardiac death includes deaths due to CHF and all other documented cardiac 
causes.   
Non-cardiac death includes deaths resulting from atherosclerosis-, medical-, and trauma-related 
non-cardiac causes, accidents, suicides, and other, unknown, or unclassifiable causes.   
3.2.3 Statistical Analyses 
Baseline characteristics are presented by vital status and by cause of death.  Statistical comparisons were 
made between groups of patients defined by the 4 mutually exclusive causes of death (alive patients were 
excluded).  Chi-square test was used to compare categorical variables, and Wilcoxon non-parametric test 
was used to compare continuous variables.   
 For all time-to-event analyses, the date of the initial revascularization procedure was considered 
time “zero,” and patients remained in the “no CABG” group until the time that they received a CABG, at 
which point they joined the “CABG” group.  Cumulative mortality rates in the CABG and no CABG (i.e. 
PTCA only) groups were estimated using the transient-state method12 and compared using the log-rank 
test.13   
 Multivariate analysis was conducted using Wei-Lin-Weissfeld (WLW) competing risks 
regression,14 which is an extension of the traditional Cox proportional hazards regression that allows 
multiple competing outcomes to be modeled simultaneously.15  Patients were considered to be at risk for 
all cause-specific mortality outcomes until the time of either censoring or death.  Since the 4 causes of 
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death are mutually exclusive endpoints, patients who died were considered to have had an “event” for the 
specific cause of their death and censored for the other 3 endpoints at the time of death.  An initial 
competing risks model was constructed to estimate the unadjusted effect of CABG (vs. no CABG) on the 
4 causes of death and to test for departures from the proportional hazards assumption.  The multivariate 
model was then built by allowing potentially confounding baseline characteristics to enter in using 
forward selection (entry criterion p<0.05 for main effects).  Known predictors of mortality,16 age, gender, 
race, diabetes status, hypertension, CHF, renal dysfunction, peripheral vascular disease (PVD), and 
malignancy, were forced in the model if they did not enter in during the forward selection procedure.  The 
time-dependent CABG variable was then added to the model, and covariates with p>0.01 were removed 
using backward selection.  Missing values (<3% of values for any variable) for clinical history variables 
included in the final multivariate model were set to the mean value for continuous variables and zero for 
binary variables; thus, binary covariates may be interpreted as the known presence of the respective risk 
factors.  Differential effects of CABG on the 4 cause-specific mortality outcomes were tested in the 
multivariate model.  Statistical interactions between CABG and diabetes status on each cause of death 
were also tested.  In the presence of any significant interactions, two separate multivariate models were 
constructed, one for patients with diabetes and one for those without diabetes.  Lastly, standard Cox 
regression was utilized to estimate the independent effect of CABG on all-cause mortality.17 
 Estimates of relative risk (RR), 95% confidence intervals (CI), and p-values are reported.  P<0.05 
are considered statistically significant.  All statistical analyses were performed using SAS version 8.2 
(Cary, NC).   
3.3 RESULTS 
Three thousand-six hundred-and ten (N=3610) BARI participants underwent initial coronary 
revascularization and were followed for an average of 7.7 years.  Patients receiving CABG included those 
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who received CABG as the initial revascularization (n=1517), and those who received PTCA as the initial 
procedure and “crossed over” to CABG during follow-up (n=722), 52% of which occurred within 6 
months of initial treatment with PTCA.  There were a total of N=1371 patients who received only PTCA 
during the course of follow-up.   
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Figure 3.1  Vital status and causes of death (among patients who died) over 7.7 years 
of follow-up 
 
At the end of the follow-up period, 83% of patients (n=2989) were alive and 17% (n=621) had died 
(Figure 3.1).  Three percent (n=107) of patients died of sudden cardiac death, 3% (n=109) MI, 2% (n=68) 
CHF and other cardiac causes, and 9% (n=337) non-cardiac causes.  Of all deaths, 17% were attributed to 
sudden cardiac death, 18% to MI, 11% to CHF and other cardiac, and 54% to non-cardiac causes. 
 Comparison of baseline characteristics by cause of death is presented in Table 3.1.  Among 
patients who died, mean age at baseline, presence of diabetes, history of MI, CHF, angina duration of at 
least 1 year, ST-segment depression on baseline ECG, and ejection fraction (EF) <50% differed 
significantly by cause of death.  Those patients who died suddenly were younger than patients who died 
of other causes.  Compared to surviving patients, those who died from sudden cardiac death had more 
extensive CAD, depressed LV function, prior MI, and abnormalities on the resting electrocardiogram and 
more persistent angina over the year before revascularization. 
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3.3.1 Unadjusted Effect of CABG on Causes of Death 
Unadjusted mortality rates were 17% (251/1517) among patients who underwent CABG as the initial 
revascularization, 13% (97/722) among patients who received CABG as a subsequent procedure, and 
20% (273/1371) among patients who never received CABG.  Transient-state Kaplan-Meier curves 
comparing cardiac and non-cardiac death rates between the CABG and no CABG groups are presented in 
Figure 3.2.   
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Figure 3.2  Kaplan-Meier curves for cardiac and non-cardiac death by CABG status 
 
 Cardiac mortality among patients who underwent CABG and those who did not were similar over 
time, with an early preponderance of events and a steady increase over the remaining follow-up period.  
7.5 years after initial revascularization, cardiac death rates in the CABG and no CABG groups were 7.3% 
and 8.6%, respectively (p=0.93).  Non-cardiac death rates were also similar in the CABG and no CABG 
groups throughout the follow-up period and at 7.5 years (9.7% vs. 9.9%, respectively; p=0.84).   
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Kaplan-Meier rates for specific causes of death at 7.5 years are presented in Figure 3.3.   
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Figure 3.3  7.5-Year cumulative rates for specific causes of death by CABG status 
 
 Patients who underwent CABG (compared to those that did not) had a significantly lower 
incidence of sudden cardiac death (2.4% vs. 3.9%, p=0.01) but similar rates of death due to MI (3.2% vs. 
3.1%, p=0.64), CHF and other cardiac (1.9% vs. 1.9%, p=0.59), and non-cardiac causes (9.7% vs. 9.9%, 
p=0.84).  Unadjusted competing risks analysis demonstrated consistent results.  Revascularization with 
CABG was associated with a significantly lower relative risk of sudden death (RR=0.62, 95% CI 0.42-
0.91, p=0.01) but was not associated with the other causes of death individually (MI: RR=1.10, 95% CI 
0.75-1.61, p=0.63; CHF and other cardiac: RR=1.14, 95% CI 0.70-1.87, p=0.59; non-cardiac: RR=0.98, 
95% CI 0.79-1.22, p=0.84) or these 3 causes of death combined (RR=1.02, 95% CI 0.86-1.22, p=0.80).   
3.3.2 Multivariate Analyses 
Adjusting for confounding predictors of mortality had little effect on the relative risks for CABG on the 
mortality outcomes (Table 3.2).  Revascularization with CABG did not significantly impact all-cause 
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mortality (RR=0.90, 95% CI 0.77-1.06, p=0.19).  Examination of the cause of death indicated that CABG 
was associated with a significantly lower risk of sudden cardiac death (RR=0.60, 95% CI 0.41-0.88, 
p=0.01) but was not associated with other causes of death individually (MI: RR=1.06, 95% CI 0.72-1.56, 
p=0.76; CHF and other cardiac: RR=1.10, 95% CI 0.67-1.79, p=0.72; non-cardiac: RR=0.93, 95% CI 
0.75-1.16, p=0.93) or combined (RR=0.98, 95% CI 0.82-1.17, p=0.83).  Moreover, the impact of CABG 
on sudden cardiac death was significantly different than the effect of CABG on all other causes of death 
combined (RR=0.60 vs. 0.98, p=0.02).  The multivariate model also revealed a statistically significant 
interaction between CABG and diabetes status for death due to MI (test of interaction p=0.04) but not any 
of the other causes (sudden death p=0.92; CHF/other cardiac p=0.19; non-cardiac p=0.53).  Therefore, we 
examined the effect of CABG on cause-specific mortality separately for non-diabetic and diabetic 
patients.  Multivariate competing risks models stratified by diabetes status are presented in Table 3.2.   
 Among patients without diabetes, revascularization with CABG significantly decreased the risk 
of sudden cardiac death (RR=0.61, 95% CI 0.38-0.97, p=0.04)  but did not significantly impact any of the 
other causes of death (MI: RR=1.51, 95% CI 0.92-2.46, p=0.10; CHF/other cardiac: RR=1.49, 95% CI 
0.74-2.99, p=0.26; non-cardiac: RR=0.99, 95% CI 0.77-1.29, p=0.96) or overall mortality (RR=1.01, 95% 
CI 0.83-1.23, p=0.94) .  In diabetic patients, CABG was associated with a 32% lower risk of long-term 
mortality (RR=0.68, 95% CI 0.52-0.90, p=0.01), and there was a statistically non-significant trend of a 
protective effect on sudden death (RR=0.55, 95% CI 0.28-1.10, p=0.09) and also MI death (RR=0.54, 
95% CI 0.28-1.02, p=0.06).  Revascularization with CABG was not associated with CHF-related 
(RR=0.69, 95% CI 0.34-1.39, p=0.30) or non-cardiac (RR=0.80, 95% CI 0.54-1.19, p=0.27) mortality in 
diabetic patients.   
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3.3.3 Further Examination of Sudden Cardiac and MI Deaths 
Kaplan-Meier curves were created to further investigate the impact of CABG on sudden cardiac death and 
MI death stratified by diabetes status (Figures 3.4 and 3.5).   
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Figure 3.4 Comparison of sudden death rates in CABG and No CABG groups stratified by diabetes 
 
In patients without diabetes, the sudden death event curves diverged steadily over time, and 7.5 years 
after initial revascularization, the cumulative rate of sudden cardiac death was significantly lower in 
patients who underwent CABG versus no CABG (2.0% vs. 3.3%, respectively, p=0.04).  A similar effect 
of CABG was observed in patients with diabetes, with 7.5-year sudden death rates of 4.4% and 7.7% 
(p=0.08) in the CABG and no CABG groups, respectively.   
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Figure 3.5 Comparison of MI death rates in CABG and No CABG groups stratified by diabetes 
 
MI-related mortality among patients without diabetes occurred more frequently in the first several weeks 
after the initial procedure in the CABG group; during 7.5 years of follow-up, the cumulative event rate 
curves converged such that the MI death rate was 2.7% in the CABG group and 2.0% in the no CABG 
group (p=0.10).  In contrast, among patients with diabetes, the MI death rate was slightly higher in the 
CABG group during the first 2 years of follow-up; however, by 7.5 years, the cumulative MI death rate 
was significantly lower in patients who underwent CABG compared to those that did not (5.4% vs. 
10.2%, p=0.04).   
3.4 DISCUSSION 
CABG had differential effects on various causes of long-term mortality in the BARI cohort of 
revascularized patients.  Revascularization with CABG significantly decreased the risk of sudden cardiac 
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death but did not impact other causes of death.  Furthermore, the protective effect of CABG on sudden 
death was observed in patients regardless of the presence or absence of treated diabetes.  
 Why might one expect CABG to reduce the risk of sudden cardiac death, but not necessarily 
other specific causes of cardiac death?  While the mechanism of sudden death in the setting of coronary 
artery disease is complex, it commonly occurs secondary to ventricular arrhythmias18, 19 (often ventricular 
tachycardia that degenerates into ventricular fibrillation20), triggered by myocardial ischemia.21  In 
general, patients receiving CABG are more completely revascularized and have the advantage of a greater 
relief of myocardial jeopardy than those receiving PTCA which targets a more limited extent of a given 
coronary artery.22, 23  Thus, we suggest that patients in the BARI cohort who received CABG had greater 
and more durable protection against myocardial ischemia which preferentially protected against acute 
environmental events which may heighten susceptibility to a ventricular arrhythmia. 
 Our results may have important clinical implications for guiding CAD treatment strategies.  
Specifically,   revascularization with CABG may be preferred in patients who are identified as having an 
increased risk of sudden cardiac death due to extensive CAD,6, 24 history of ventricular arrhythmia,25 ECG 
abnormalities, and impaired LV function.26  If PCI is the intervention ultimately chosen in patients at 
particularly high risk for sudden death, more complete revascularization may be wise.  Prior studies in 
CASS emphasized the importance of complete surgical revascularization in patients with depressed LV 
function.  However, as noted in the BARI cohort of patients with multivessel disease, the majority treated 
with PTCA had less complete revascularization than CABG-treated patients, and even in current practice, 
many PCI-treated patients receive treatment in only one coronary segment.  While this approach to PCI 
does not appear to compromise overall survival, as per BARI in those without treated diabetes, the current 
study suggests that PTCA as performed in 1988-1991 left patients at risk for sudden death in contrast to 
those revascularized with CABG.  Patients who are not suitable candidates for bypass surgery may benefit 
from added measures to prevent sudden death, such as prophylactic placement of implantable cardiac 
defibrillators, which has been shown to substantially improve survival in the CAD population by 
preventing sudden death.27 
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 Of note, PTCA in BARI preceded the routine use of both bare metal and drug-eluting stents, and 
similarly, CABG has continually progressed with better perioperative management, a higher use of 
arterial grafting, and improved techniques with minimally invasive and off pump surgery as options.28, 29  
In the context of these developments, are the BARI results relevant?  Yes – as described above, the subset 
of patients who benefited most from CABG were those at high risk of sudden cardiac death, as 
characterized by extensive CAD, depressed LV function, abnormalities on the resting electrocardiogram, 
etc.  By way of analogy, PCI is currently challenging CABG as an alternative for revascularization of 
high-risk patients with triple vessel disease or left main disease, domains historically reserved for CABG.  
Whether or not current methods of PCI will eliminate or minimize the historical advantage of CABG in 
selected high-risk subsets is under study in several current large randomized trials.  To this end, our data 
corroborate the need for rigorous evaluation of revascularization strategy of very high risk patients, in 
particular, those at high risk of sudden cardiac death. 
 Multivariate analysis of cause-specific mortality also revealed a statistically significant 
interaction between diabetes status and CABG for MI death, indicating a differential impact of CABG on 
MI death in patients with and without diabetes.  Although the relative risks associated with CABG for MI 
death were not significantly different from one (i.e. no effect) in the two stratified models, it is notable 
that in the non-diabetic population CABG was associated with a greater long-term risk of MI death while 
in the diabetic population CABG was associated with a lower long-term risk of MI death.  This is 
consistent with the previous report by Detre et al.30 that demonstrated that among revascularized patients 
who have an MI, CABG offered greater protection against long-term mortality in diabetic patients 
compared to non-diabetic patients.   
 Whereas comparison of the strategy of initial revascularization with CABG versus PTCA is best 
accomplished in an intention to treat analysis of a randomized clinical trial, the purpose of this analysis 
was to evaluate the impact of receiving (versus not receiving) a CABG on various causes of mortality.  
Therefore, undergoing CABG, as either an initial procedure or a subsequent procedure, was the exposure 
of primary interest.  Since BARI registry patients met every eligibility criteria for the randomized trial 
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except a willingness to be randomly assigned to treatment, our purpose was best served by including both 
the randomized and registry cohorts in this analysis and by considering treatment with CABG at any time 
during the BARI study as our key covariate.  The same patient sample and methodology were used in 
BARI report by Detre et. al. to evaluate the effect of CABG on survival after MI.30 
 Competing risks analysis of cause-specific mortality in the BARI study provided additional 
information beyond standard Cox regression analysis of overall mortality or even cardiac mortality.  All-
cause mortality is a common primary endpoint in clinical studies, including BARI, since death, regardless 
of its cause, is an important and clinically meaningful outcome.  This pertains especially to studies that 
evaluate medical treatments designed to prolong survival.  From a methodologic perspective, clearly 
defined endpoints such as all-cause mortality are more easily verified, and the data will more often be 
complete.  Despite such advantages, important implications of the disease process and treatment effect 
may be missed by not considering specific causes of death.  Holmes et al. reported that the ratio of cardiac 
to non-cardiac death rates tends to decrease as patients age within a study cohort and as follow-up time 
increases.4  This was evident in BARI, and a preponderance of non-cardiac deaths may obscure accurate 
interpretation of studies investigating long-term treatment effects, particularly in an aging patient 
population.   
 The study shares the weaknesses of an observational study in addition to the difficulty of 
determining the actual cause of death.  A strength of the BARI study however is the manner in which 
cause of death was determined. An independent Morbidity and Mortality Committee comprised of 
cardiologists was included in the original design of BARI, and the initial five year results showing a 
survival benefit with CABG in patients with treated diabetes was greatly enhanced by determining that 
the difference was entirely due to cardiac mortality. 
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3.5 CONCLUSION 
In BARI, revascularization with CABG had a different impact on specific causes of long-term mortality 
in patients with multivessel coronary artery disease.  CABG significantly decreased the risk of sudden 
cardiac death, irrespective of diabetes status, while not significantly altering the risk of other causes of 
death.  Evaluation of specific causes of death provided insights that may be useful for guiding treatment 
selection and developing strategies to improve long-term survival after coronary revascularization. 
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Table 3.1  Baseline characteristics by vital status and cause of death 
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Sudden  
Death MI
CHF/Other 
Cardiac
Non-    
Cardiac P*
(n=2989) (n=107) (n=109) (n=68) (n=337)
Demographic profile
Age, in years 61±10 62±9 64±10 67±9 66±9 <0.01
Male 75 77 63 60 68 0.09
White race 93 82 89 85 89 0.31
Black race 4 12 10 10 8
Post 
Medi
Tr
My
Co
Peri
Hyp
Re
Mal
Clinical
For
Cur
Stabl
Stabl
Uns
Ang
Maj
ST
Maj
Angiog
Tr
Proxi
Eject
Left
Catego
Alive
Dead (Cause of Death)
*  Com
†  Ejectio
high school education 36 28 26 25 29 0.33
cal history
eated diabetes 15 31 36 47 30 0.04
ocardial infarction 51 65 64 62 51 0.01
ngestive heart failure 5 14 23 25 14 0.03
pheral vascular disease 13 21 26 29 29 0.40
ertension 46 55 64 69 58 0.20
nal dysfunction 1 7 6 12 5 0.21
ignancy 4 7 6 10 12 0.16
 profile
mer smoker 46 50 40 44 47 0.52
rent smoker 23 25 27 21 26
e angina class 1 or 2 16 10 13 12 13 0.27
e angina class 3 or 4 15 9 16 24 15
table angina/ non-Q-MI 68 80 72 65 71
ina duration ≥1 year 39 34 55 43 49 0.01
or Q-wave 16 23 25 22 23 0.96
 depression 5 12 8 21 6 <0.01
or ECG abnormality 40 54 52 54 52 0.97
raphic profile
iple-vessel disease 37 49 46 49 40 0.28
mal LAD disease 38 38 43 25 40 0.12
ion fraction <50% † 14 28 24 34 20 0.02
-sided/ mixed dominance 14 23 26 12 17 0.06
rical variables are presented as column percentages, continuous variables as mean±SD.
pares 4 causes of death among patients who died.
n fraction data was missing for 462 patients.
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No. of 
Events RR* 95% CI P
No. of 
Events RR* 95% CI P
No. of 
Events RR* 95% CI P
Impact of CABG (vs. no CABG) on:
   All-cause mortality 621 0.90 0.77-1.06 0.19 416 1.01 0.83-1.23 0.94 205 0.68 0.52-0.90 0.01
   Sudden cardiac death † 107 0.60 0.41-0.88 0.01 74 0.61 0.38-0.97 0.04 33 0.55 0.28-1.10 0.09
   MI death ‡ 109 1.06 0.72-1.56 0.76 70 1.51 0.92-2.46 0.10 39 0.54 0.28-1.02 0.06
   CHF/other cardiac death 68 1.10 0.67-1.79 0.72 36 1.49 0.74-2.99 0.26 32 0.69 0.34-1.39 0.30
   Non-cardiac death 337 0.93 0.75-1.16 0.54 236 0.99 0.77-1.29 0.96 101 0.80 0.54-1.19 0.27
‡   The impact of CABG on MI death was significantly different in non-diabetic and diabetic patients (test of interaction p=0.04).
CABG indicates coronary artery bypass graft; RR relative risk; CI confidence interval
*   Adjusted for: diabetes, age, gender, race, smoking, congestive heart failure, hypertension, major ECG abnormality, peripheral vascular 
disease, renal dysfunction, left/mixed dominance, ejection fraction, and malignancy.
†   Among all patients, the impact of CABG on sudden cardiac death was significantly different than on all other causes of death combined 
(test of interaction p=0.02).
All Patients (N=3610) No Diabetes (n=2968) Diabetes (n=642)
  
Table 3.2  Relative Risks Associated with CABG for Overall and Specific Causes of Death 
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4.1 INTRODUCTION 
Percutaneous transluminal coronary angioplasty (PTCA) is an established and effective revascularization 
strategy for patients with coronary artery disease (CAD).1, 2  The appeal of achieving desirable results by a 
minimally invasive means is, however, offset by the need for subsequent procedures due to restenosis and 
atherosclerotic disease progression.  In the NHLBI3 and Mayo Clinic4 PTCA Registries, 35-50% of 
patients who underwent an initially successful balloon angioplasty required subsequent coronary artery 
bypass surgery (CABG) or repeat PTCA over the next 5 to 10 years.  Factors that have been shown to 
significantly increase the long-term risk of repeat revascularization include male gender, diabetes, 
unstable angina, lesion length, and not fully successful initial dilation.5-8   
 Predictors of recurrent coronary interventions have been previously described in the PTCA 
population.  However, these analyses have generally been limited to the first subsequent procedure event, 
and thus, may not have considered the full impact of various risk factors on recurrent revascularizations.  
Although percutaneous coronary intervention has evolved substantially since balloon angioplasty, 
evaluation of multiple subsequent revascularization procedures over an extended period of time among 
patients who underwent successful initial PTCA may provide information regarding the impact of specific 
risk factors on the progression of CAD and, to a lesser degree, on restenosis.  Given the substantial long-
term cost associated with PCI treatment driven largely by subsequent interventions,9, 10 identification of  
factors that impact recurrent revascularizations may provide useful insights for predicting patient 
prognosis as well as for guiding treatment strategies.  We analyzed the Bypass Angioplasty 
Revascularization Investigation (BARI) cohort for this purpose. 
 The specific aim of this analysis was to identify factors related to repeat revascularization after 
successful initial PTCA, and to evaluate the impact of these predictors on multiple revascularization 
outcomes occurring over 10 years of follow-up. 
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4.2 METHODS 
4.2.1 Study Design 
BARI was designed to compare an initial revascularization strategy of CABG versus PTCA on long-term 
mortality in patients with multivessel coronary artery disease.  A detailed description of the trial has been 
published previously.11  In brief, eligibility criteria included clinically severe angina or evidence of 
ischemia requiring revascularization and angiographically documented CAD involving 2 or 3 vessels 
amenable to revascularization by either CABG or PTCA.  Exclusion criteria included severe left main 
disease, prior coronary revascularization, and acute myocardial infarction (MI) 24-hours prior to the 
initial procedure.  Participants were enrolled from 18 clinical sites in the United States and Canada 
between August 1988 and August 1991.  Of the 4107 eligible patients identified, 1829 patients gave 
written informed consent and were randomized to either CABG or PTCA.  Eligible patients who declined 
randomization were given the opportunity to participate in the BARI registry, in which the patients and 
their physicians selected the initial revascularization strategy but had similar follow-up schedules as the 
randomized patients.  This analysis includes participants in the BARI randomized trial and registry who 
underwent initial PTCA.   
 Identical baseline data were collected for BARI randomized and registry patients, which included 
demographic descriptors, clinical history, 12-lead electrocardiogram (ECG) parameters, coronary 
angiography measurements, angina, and other risk factors.  Although baseline and procedural angiograms 
were evaluated by a central laboratory for patients in the randomized trial, only clinical site evaluations 
were obtained for the registry participants.  Therefore, angiographic data based on site interpretation were 
used in this analysis.  Patients with missing baseline angiograms were excluded (n=38).  Follow-up data 
were obtained during clinic visits at 4 to 14 weeks and at 1, 3, and 5 years, and telephone contacts at 6 
months, 2, 4, 5 years, and annually thereafter.  At the time of a vital status sweep undertaken on March 
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31, 2000, BARI patients who had reached 10 years of follow-up were censored, and patients who fell 
short of the decade mark continued to be followed until their 10-year anniversary.   
 The present analysis is a long-term evaluation of factors related to repeat revascularizations 
including insight regarding restenosis and disease progression.  Since cardiovascular complications 
occurring during or shortly after percutaneous intervention are generally attributed to procedural factors 
(i.e. technical failure, operator skills, and inadequate completeness of revascularization), this analysis was 
limited to patients who underwent a successful initial PTCA, which was defined as having at least one 
≥50% lesion successfully dilated and not experiencing MI, subsequent revascularization, or death within 
30 days of the index procedure.  Patients were excluded due to at least one of the following early failure 
(in-hospital) events: total angiographic failure (n=201), MI (n=58), subsequent CABG (n=185), 
subsequent PTCA (n=105), and death (n=17).  This analysis also excluded patients who received new 
interventional devices during the initial PTCA procedure, including: atherectomy (n=33), bare metal stent 
(n=11), and laser (n=6).  Thus, the present study evaluates patients who underwent balloon angioplasty in 
the pre-stent era.   
4.2.2 Angiographic Definitions 
Diseased vessels were determined from the anterior, lateral, and inferoposterior coronary perfusion 
territories supplied by a vessel with a significant lesion.  Lesions residing in a vessel with reference 
diameter >1.5mm were considered significant if stenosis was ≥50% and totally occluded if stenosis was 
≥99%.  Successful lesion dilation was characterized by residual stenosis <50%, ≥20% reduction in 
stenosis, and TIMI grade 3 flow.  Angiographic success of the index procedure was considered to be 
‘partial’ if some but not all attempted significant lesions were successfully dilated, and ‘total’ if all 
attempted significant lesions were successfully dilated.  Lastly, the initial PTCA was considered an 
incomplete revascularization (IR) if any significant lesions were left remaining. 
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4.2.3 Statistical Methods 
Baseline clinical and angiographic characteristics were compared using the Chi-square test for categorical 
variables and the Cochran-Armitage trend test for ordinal variables.  For angiographic data, we were 
interested in assessing the presence of disease at baseline, as well as any residual disease following initial 
revascularization.  Therefore, lesion characteristics were examined as binary variables (indicating 
presence vs. absence) and as 3-level categorical variables (absent, present and attempted, and present but 
not attempted).    
 The main outcome was time-to-repeat revascularization with either CABG or PTCA.  For all 
time-to-event analyses, the date of the initial PTCA was considered to be time “zero.”  PTCAs performed 
in multiple stages were counted as a single procedure, and the date of the first stage was considered to be 
the date for that procedure.  Patients were censored at the time of death.  Kaplan-Meier12 curves were 
constructed to examine temporal trends in the first repeat revascularization event.  Nelson-Aalen curves 
were created to estimate the cumulative number of repeat revascularization procedures received per 100 
patients over time.   
 Multivariate analyses were initiated by identifying predictors of the first repeat revascularization 
event using Cox proportional hazards regression.13  Clinical and angiographic characteristics were 
allowed to enter into the model using forward selection (entry criterion p<0.10) and then, angiographic 
PTCA procedural variables were allowed to enter (entry criterion p<0.10).  Covariates with p≥0.05 were 
later removed using backward selection.  A separate Cox model was constructed using “second repeat 
revascularization” as the endpoint with the same model-building procedures but forcing in predictors of 
the first event.  The final model included variables identified by either model-building process.  We tested 
for possible interactions between covariates in the main effects model based on biological plausibility (i.e. 
diabetes and evidence of diffuse disease), and statistical interactions with p<0.05 were retained.  Missing 
values (<3% for any variable) were set to the mean value for continuous variables and zero for binary 
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variables, and the proportional hazards assumption was checked for each covariate in the model by 
examining Kaplan-Meier curves.   
 A multiple outcomes model was created using methods described by Prentice-William-Peterson 
(PWP)14 an extension of Cox regression that allows multiple recurrent events to be modeled 
simultaneously using robust variance estimates.  The PWP (or ‘conditional’) approach estimates the 
probability of having a subsequent event conditional on having experienced a prior event.  Compared to 
other statistical methods for analyzing multiple outcome events data, the PWP approach is efficient and 
powerful in detecting differences between exposure groups.15  The time to each subsequent 
revascularization events is measured as the time since the previous event.  We initially considered 
modeling the first 4 repeat revascularization events per patient.  Preliminary PWP models indicated that 
none of the predictor variables had a significantly different impact on the third and fourth events (all 
p>0.10).  Therefore, PWP analysis was limited to the first 3 repeat revascularizations, which ensured 
sufficient sample size for analysis in each of the latter event categories    
 Multivariate PWP regression was utilized to investigate the effect of each predictor on the first, 
second, and third repeat revascularization events.  The PWP model initially allowed for separate 
associations between each covariate and the 3 outcomes; only those covariates with a significantly 
different impact on the defined endpoint, or combination of endpoints, are presented as outcome-specific 
estimates (test of equal associations p<0.05).  Relative risk estimates for such ‘uncommon effect’ 
predictors may be interpreted as the probability associated with a given factor of having: a first repeat 
revascularization event; a second repeat revascularization event among those who had a first event; and a 
third event among those who experienced the first and second events.  Covariates that had a similar 
impact on the 3 outcomes were included in the model as a single common-effects variable indicating an 
average effect of the predictor on the long-term subsequent revascularization rate.   
 Since patients may not receive subsequent revascularization because they die before having an 
opportunity to be treated or because they are poor candidates for subsequent revascularization due to 
increased perioperative risk, we were concerned that our results may be affected by the occurrence of 
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deaths (survival bias) as well as the perceived risk of death based on comorbidities (selection bias).  To 
address this concern, we compared PWP regression results in the overall cohort with a subgroup of 
patients who had lower risk of long-term mortality based on propensity scoring.16  The probability of 
death (the propensity score) was estimated for each patient using a multivariable model for 5-year 
mortality previously reported in BARI;17 the "lower risk" strata was defined by propensity scores in the 
lower 70th percentile.  
 Estimates of relative risk (RR), 95% confidence intervals (CI), and p-values are reported, and 
p<0.05 is considered statistically significant.  All statistical analyses were performed using SAS 9.1 
(Cary, NC).   
4.3 RESULTS 
4.3.1 Repeat Revascularizations Over 10 Years of Follow-Up 
In BARI, 1606 patients underwent successful initial PTCA and were followed over an average of 10.6 
years.  Subsequent revascularizations received are presented in Figure 4.1.   
 
  43
All Patients          
Receiving Initial PTCA
(N=1606)
None
(n=276)
None
(n=85)
CABG
(n=45)
PTCA
(n=76)
None
(n=693)
None
(n=265)
None
(n=109)
CABG
(n=4)
PTCA
(n=15)
None
(n=22)
PTCA
(n=9)
None
(n=7)
PTCA
(n=206)
PTCA
(n=610)
CABG
(n=128)
PTCA
(n=31)
CABG
(n=303)
CABG
(n=7)
Zero Repeat Revascularizations
1ST Repeat Revascularization Event
2ND Repeat Revascularization Event
3RD Repeat Revascularization Event
43% 57%
23%
9%
 
Figure 4.1  Subsequent revascularizations received over 10 years after successful initial PTCA 
 
Following initial treatment, 43% of patients (n=693) did not undergo any additional procedures and 57% 
(n=913) received a first repeat revascularization, 38% (n=610) with PTCA and 19% (n=303) with CABG.  
Among those who underwent a first repeat PTCA, 55% (n=334) received a second subsequent procedure 
(206 with PTCA and 128 with CABG), of which 42% (n=140) went on to receive a third procedure (91 
with PTCA and 49 with CABG).  Among patients who received CABG as the first repeat 
revascularization, 13% (n=38) underwent a second subsequent procedure (31 with PTCA and 7 with 
CABG), and 24% (n=9) of these patients underwent a third procedure.   
4.3.2 Baseline Characteristics 
Baseline characteristics associated with repeat revascularization with either CABG or PTCA are 
presented in Table 4.1.  Gender was significantly related to a first procedure, with 60% of men 
undergoing additional procedures compared to 50% of women (p<0.001).  Other clinical characteristics 
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that were associated with a significantly greater risk of a subsequent revascularization included diabetes 
(p=0.04), unstable angina (p=0.03), and angina duration of at least 1 year (p=0.03).  The subsequent 
procedure rate was significantly lower in patients 65 years and older (p<0.001), former and current 
smokers versus never smokers (p<0.001) and in patients without, compared to those with, ST elevation on 
baseline ECG (p<0.001).   
 Angiographic predictors of subsequent revascularization are presented in Table 4.2.  Myocardial 
jeopardy index demonstrated a significant relationship between overall angiographic severity at the time 
of initial PTCA and the need for additional treatment (p=0.01).  Nearly one-third of patients had triple 
vessel disease at baseline, which was associated with a higher incidence of subsequent revascularization 
compared to double vessel disease (61% vs. 55%, p=0.04).  All BARI participants had multivessel disease 
by eligibility criteria; thus, we examined the disease distribution at baseline by forming mutually 
exclusive categories of the diseased coronary vessels.  Among patients with double vessel disease, the 
subsequent revascularization rate was 60% in those with significant lesions in the left anterior descending 
(LAD) and left circumflex (LCx) arteries, 54% in LAD and RCA, and 52% in LCx and right coronary 
artery (RCA).  LAD disease appeared to play an important role in the need for further interventions, such 
that presence at baseline (p=0.03) and evidence of residual LAD disease after initial PTCA (p=0.05) were 
associated with a higher repeat revascularization rate over long-term follow-up.  In particular, proximal 
LAD disease that was present at baseline or left untreated was related to a subsequent procedure (p=0.02 
and p=0.06, respectively).   
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4.3.3 Kaplan-Meier and Nelson-Aalen Curves 
A Kaplan-Meier curve of the proportion of patients who underwent at least one repeat revascularization is 
presented in Figure 4.2.   
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Figure 4.2  Kaplan-Meier curve for time to the first repeat revascularization event 
 
Following successful initial PTCA, there was a steep, early rise in the percentage of patients who received 
additional procedures, such that nearly half of all patients who underwent subsequent revascularization 
did so within one year of the index PTCA procedure; a more gradual increase was observed over the 
remaining follow-up period.  Among patients who underwent at least one subsequent revascularization, 
the median time to the first event was 7 months for those receiving PTCA (n=610) and 28 months for 
those receiving CABG (n=303). 
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 A Nelson-Aalen curve for the estimated cumulative number of repeat revascularizations per 100 
patients is presented in Figure 4.3.   
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Figure 4.3  Nelson-Aalen estimates for cumulative number of repeat procedures per 100 
patients 
 
The cumulative number of repeat procedures increased markedly during the first year, and continued to 
rise steadily throughout the follow-up period, reflecting patients who underwent a first subsequent  
revascularization and also those who received multiple additional procedures.   
4.3.4 Cox Model for the First Repeat Revascularization Outcome 
Several predictors of the first subsequent revascularization were identified using multivariate Cox 
regression analysis (Table 4.3).  Following initial treatment with PTCA, male gender, diabetes, and 
unstable angina (compared to stable or atypical angina) were associated with a significantly increased risk 
of repeat revascularization, and age ≥65 years, smoking history, and ST-segment elevation were 
associated with a significantly lower risk.  Angiographic characteristics that were independently 
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predictive of the need for additional treatment included proximal LAD disease, presence of diffuse 
lesions, and an incomplete revascularization during the index PTCA.  Renal dysfunction was not related 
to the first repeat revascularization event but was associated with a significantly increased risk for the 
second event. 
4.3.5 PWP Model for Multiple Repeat Revascularization Outcomes 
PWP model estimates for differential covariate effects on the multiple repeat revascularization outcomes 
are presented in Table 4.4.  Among patients who underwent successful initial PTCA, fewer than 5% had 4 
or more procedures, and 80% of the observed subsequent procedures were accounted for in this analysis 
(Table A6.1).  Consistent with Cox regression analysis, men were more likely than women to undergo a 
first subsequent revascularization (RR=1.44, p<0.001).  However, among patients who received a first 
repeat procedure, the risk of undergoing a second procedure did not differ by gender (RR=1.00, p=0.97), 
and then among those who received a second repeat procedure, men were significantly less likely to 
undergo a third revascularization compared to women (RR=0.64, p=0.01).  The differing effect of gender 
on the number of recurrent treatments was significant (test of equal associations: RR=1.44 vs. 1.00 vs. 
0.64, p<0.001).  Similarly, incomplete revascularization was associated with a higher risk of a first repeat 
revascularization event (RR=1.13, p=0.07), but conditional on having received one subsequent treatment, 
incompletely revascularized patients had a marginally lower likelihood of undergoing second and third 
repeat procedures (RR=0.86, p=0.09).  The impact of IR on the number of subsequent revascularizations 
was significantly different (RR=1.13 vs. 0.86, p=0.01). Proximal LAD disease and smoking history were 
significantly associated with the first repeat revascularization event (RR=1.24, p<0.01 and RR=0.71, 
p<0.001, respectively), but were not associated with subsequent procedures beyond the first (RR=0.95, 
p=0.58 and RR=0.96, p=0.63, respectively).   
 The PWP conditional model demonstrated a significant common effect of several predictors on 
the number of repeat revascularizations.  Diabetes was associated with an estimated 43% increase in the 
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subsequent revascularization rate over 10 years after initial PTCA (RR=1.43, p<0.001).  This means that 
diabetes increased the risk of a first repeat revascularization event, and then among patients who 
experienced a first event, diabetes was again significantly related to higher rates of a second subsequent 
procedure, and similarly for a third procedure.  A sustained effect was also demonstrated for renal 
dysfunction (RR=1.75, p<0.001), unstable angina (RR=1.15, p=0.01), and presence of diffuse lesions 
(RR=1.13, p=0.03).  Age ≥65 years and ST elevation were associated with a lower common effect on the 
subsequent revascularization rate (RR=0.84, p<0.01 and RR=0.52, p<0.001, respectively).   
4.3.6 Assessment of Survival and Selection Bias 
Ten-year cumulative mortality rate was markedly higher among patients who did not receive subsequent 
revascularization compared to those who did (32% vs. 21%, log-rank p<0.001), which suggested a 
potential survival bias.  Multivariate PWP analysis of a subgroup of patients with a lower predicted 
probability of death, which addressed both survival bias and treatment selection bias, resulted in estimates 
that were consistent with estimates in the overall cohort (Table A6.2). The notable exception was age ≥65 
years, which was not significantly associated with subsequent revascularizations among patients with a 
lower predicted probability of death (RR=0.93, p=0.31).   
4.3.7 Examination of Subsequent Revascularization Strategy 
To illustrate the changing effect of gender, proximal LAD disease, and incomplete revascularization on 
the multiple subsequent procedure outcomes, we compared event rates and mode of revascularization 
(either CABG or PTCA) for these patient groups.  As shown in Figure A6.1, men were more likely to 
undergo a first subsequent procedure compared to women (60% vs. 50%, p<0.01) and, in particular, to 
receive CABG for the first treatment (21% vs. 14%, p<0.01).  Among patients who had a first subsequent 
revascularization event, gender was not related to a second event (p=0.90), but of those who received a 
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second repeat procedure, a smaller proportion of men underwent a third procedure (36% vs. 52%, 
p<0.01).   
 A similar pattern was observed for proximal LAD disease and incomplete revascularization 
(Figures A6.2 and A6.3, respectively).  Patients with proximal LAD disease (compared to those without 
it) more frequently underwent a first repeat procedure (61% vs. 55%, p=0.02), particularly with CABG 
(21% vs. 18%, p=0.04).  However, among patients who had a first event, proximal LAD disease was not 
predictive of further interventions (p=0.51 and p=0.20).  Patients who received an incomplete (versus 
complete) initial revascularization were somewhat more likely to undergo a first subsequent procedure 
(58% vs. 54%, p=0.13) and significantly more likely to be treated with CABG (23.0% vs. 12.2%, 
p<0.001).  Conditional on the first repeat procedure, IR was associated with a marginally lower second 
event rate (39% vs. 44%, p=0.11), but, once again, incompletely revascularized patients were more likely 
to receive CABG for the second procedure (15.4% vs. 13.7%, p=0.06).  Among patients who underwent 
two repeat procedures, an incomplete initial revascularization was not predictive of a third intervention 
(39% vs. 41%, p=0.71).   
4.4 DISCUSSION 
Among patients who underwent successful initial PTCA in BARI, an estimated 57% received at least one 
subsequent procedure and 23% received two or more procedures over 10 years of follow-up.  The long-
term repeat revascularization rate in BARI was comparable to what has been reported from the NHLBI3 
and Mayo Clinic4 PTCA Registries in similar subset of patients (i.e. those with multivessel disease and 
successful initial balloon angioplasty).  Factors that were associated with a significantly greater risk of 
repeat revascularization included: male gender, diabetes, renal dysfunction, unstable angina, proximal 
LAD disease, diffuse disease, and incomplete revascularization.   
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 Evaluation of the multiple repeat revascularization events revealed a significantly different effect 
of gender, proximal LAD disease, and completeness of initial PTCA on the first versus latter events.  In 
BARI, patients who were male, with proximal LAD disease, and received an incomplete revascularization 
were more likely to undergo a first repeat procedure, and more importantly, to be revascularized with 
CABG for this procedure.  Given this subsequent treatment with CABG, a more durable revascularization 
strategy than PTCA,4, 18, 19 these 3 predictors were either not related or negatively associated with the need 
for additional coronary interventions.  Prior percutaneous intervention studies have reported that men are 
more frequently referred for repeat procedures compared to women,4 including more frequent subsequent 
surgical revascularization.20  Although the underlying reasons remain unclear, a possible explanation may 
be that female gender has been identified as an independent risk factor for major in-hospital CABG 
complications in both the Society for Thoracic Surgeons risk modeling21 and the EuroSCORE risk 
algorithm.22 
 Consistent with previous reports,23-26 measures of extent and severity of CAD at the time of initial 
PTCA treatment were associated with a significantly increased risk of repeat revascularizations in BARI.  
Among these multivessel disease patients, the location of the disease was a stronger independent predictor 
than the number of lesions or diseased vessels.  Significant LAD disease, particularly in the proximal 
segment, was related to subsequent revascularization.  Much of the difference in repeat revascularization 
rates between patients with and without LAD disease occurred early in the follow-up period (<1 year), 
which may reflect higher incidence of restenosis in patients who had LAD lesions treated during the index 
procedure or the need to treat residual disease in those with LAD lesions that were left untreated.   
 PWP analysis demonstrated a persisting detrimental impact of diabetes on the increasing number 
of recurrent procedures.  Diabetes was associated with a significantly greater risk of restenosis following 
balloon angioplasty6, 8, 27-29 and accelerated disease progression, which are mediated by hyperreactive 
platelets that exhibit increased adhesion, aggregation, and platelet-dependent thrombin generation.30  Our 
findings support what has been previously described regarding the role of diabetes in CAD progression, 
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and underscore the importance of intensive risk factor modification in diabetic patients undergoing 
coronary revascularization in order to maintain the benefits of initial treatment.  
 Investigation of factors related to subsequent procedures also allowed us to characterize patients 
who are likely to attain long-term success after undergoing initial percutaneous intervention.  Even in the 
presence of multivessel disease, 43% of patients who had a successful initial PTCA in BARI received no 
subsequent revascularization.  Our analyses indicate that percutaneous coronary intervention may be 
particularly effective for women and patients without the presence of diabetes, renal disease, and 
advanced CAD (as indicated by presence of unstable angina, diffuse lesions, and proximal LAD disease), 
and those in whom complete revascularization can be achieved. 
 Importantly, our findings were confirmed in a subgroup of patients with a relatively lower 
mortality risk who were, therefore, less subject to survival and treatment selection bias.  Overall, there 
was minimal evidence to suggest that early deaths and reluctance to revascularize high risk patients 
influenced the results of this analysis in a meaningful way. The only covariate that differed meaningfully 
between the 2 models was age, indicating that the seemingly ‘protective’ effect of older age may be due 
to early deaths or a reluctance to revascularize high risk patients.  A similar explanation was not evident 
for smoking history and ST elevation, established cardiovascular risk factors related to lower 
revascularization rates.  A biologically plausible explanation of our finding on smoking is a 
“preconditioning-like” effect of nicotine on the myocardium.  Animal studies suggest that brief ischemic 
episodes may promote the formation of collateral vessels and thereby increase myocardial tolerance to 
subsequent periods of prolonged ischemia.31  Smoking history may, in fact, have a lower risk of repeat 
procedures because of protection derived from collaterals vessels.  This postulate, however, cannot be 
verified due to an absence of specific angiographic data on collateral vessels.  Regarding ST elevation, it 
is possible that patients with ST elevation on baseline ECG received more aggressive medical therapy 
after initial PTCA compared to others.     
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4.4.1 Extending Study Results to the Current Era 
The introduction of drug-eluting stents in the last decade has drastically lowered restenosis rates 
following percutaneous intervention.32-34  Despite overcoming a major limitation of conventional balloon 
angioplasty, benefits conferred by drug eluting stents and adjunctive therapies (namely, the use of 
glycoprotein IIb/IIIa inhibitors) are limited to the short-term.  Even in the absence of definitive data, there 
is little reason to believe that contemporary PCIs alone (i.e. notwithstanding advances in pharmacological 
therapy) will diminish the long-term need for additional procedures, which is driven mainly by native 
disease progression in the coronary arteries.25, 35, 36  Therefore, generalizeability of our findings to the 
current PCI patient population are less likely to be affected by improvements in PCI technology and 
adjunct therapy, and more likely to be influenced by the widespread use of statins, anti-platelet 
medications, and other anti-atherogenic agents. 
4.4.2 Study Limitations 
Although extensive baseline and procedural angiographic data were obtained, follow-up angiograms were 
not systematically collected in BARI.  Without knowing which target lesions were treated during 
subsequent revascularizations, it is difficult to offer more definitive explanations and possible underlying 
mechanisms for our findings.  Nevertheless, it has been well-established that restenosis occurs most 
frequently during the first 6 months and up to 1 year after balloon angioplasty.6, 37-39  Given this timeframe 
and the fact that majority of repeat procedures during the first year were percutaneous interventions, 
which is the standard approach for treating primary restenosis,40  it is likely that in BARI, subsequent 
revascularizations during the first year were to address restenosis and those occurring after the first year 
were to treat native disease progression.  This is supported by results from a BARI ancillary study, which 
included approximately 400 patients from the randomized trial, indicating that angiographically-
documented CAD progression exceeded failure of initial revascularization as the cause of recurrent 
angina at 5-year follow-up.36 
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4.5 CONCLUSION 
Among patients who were successfully treated with initial PTCA in BARI, independent predictors of a 
first repeat revascularization event included male gender, diabetes, renal dysfunction, unstable angina, 
proximal LAD disease, diffuse disease, and incomplete revascularization.  Evaluation of multiple repeat 
revascularization events occurring over 10 years of follow-up demonstrated a significantly different effect 
of several predictors on the number of recurrent outcomes.  Male gender, proximal LAD disease, and 
incomplete revascularization were associated with a significantly increased risk of a first repeat procedure 
but were either not related or inversely related to the need for additional procedures.  Examination of 
revascularization strategy revealed that patients with these characteristics in BARI were more likely to 
receive CABG as their first subsequent treatment, and this strategy substantially decreased the need for 
further revascularizations.  Diabetes, renal dysfunction, unstable angina, and diffuse disease, on the other 
hand, had a consistent detrimental impact on the number of repeat revascularizations.  These findings 
underscore the importance of glycemic control and intensive modification of risk factors that promote 
atherosclerotic progression.  These data also indicate that women and patients with an absence of 
extensive coronary disease, diabetes, and renal disease are less likely to need further revascularizations 
and, therefore, may be particularly good candidates for initial PCI treatment. 
 Recent advances in PCI technology have significantly improved short-term outcomes but have 
not markedly decreased the long-term need for additional procedures which are driven primarily by 
disease progression.  Given the substantial economic and health burden associated with subsequent 
revascularizations, an aggressive approach to limiting disease progression is paramount.  Similarly, 
devising optimal long-term treatment plans that address cardiovascular disease as a chronic, progressive, 
and systemic condition is of great public health importance. 
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Table 4.1  Baseline characteristics associated with repeat revascularization after 
successful initial PTCA 
 
No. of Repeat
Patients Procedure
(N=1606) (n=913)
BARI study Randomized trial 717 56% 0.44
Registry 889 58%
Gender Female 432 50%
Male 1174 60% <0.001
Age < 65 y/o 992 61% <0.001
≥ 65 y/o 614 51%
Race White 1481 57% 0.56
Non-white 125 54%
Education < High school 1019 55% 0.09
≥ High school 566 60%
Prior MI No 773 58% 0.34
Yes 815 56%
CHF No 1499 57% 0.08
Yes 103 49%
PVD No 1363 58% 0.26
Yes 237 54%
Hypertension No 825 56% 0.55
Yes 778 58%
Treated Diabetes No 1327 56% 0.04
Yes 279 62%
Renal Dysfunction No 1569 57% 0.98
Yes 35 57%
Smoking History Never 478 65% <0.001
Former 724 53%
Current 404 54%
ST Elevation No 1539 58% <0.001
Yes 64 36%
Angina Status Stable/ Non-Q-MI 768 54% 0.03
Unstable 838 59%
Angina Duration ≥ 1YR No 992 55% 0.03
Yes 611 60%
Row percentages are presented.
*  P-values are based on chi-square test
P-         
value *
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Table 4.2  Baseline and procedural angiographic factors associated with repeat 
revascularization 
No. of Repeat
Patients Procedure
(N=1606) (n=913)
Myocardial Jeopardy Index ‡ < 50% 473 51% 0.01
50-65% 613 57%
66-100% 520 61%
Ejection Fraction <50% No 1194 57% 0.79
Yes 248 56%
Vessel Disease Double 1101 55% 0.04
Triple 470 61%
Diseased Vessels LAD & LCx only 379 60% 0.02
LAD & RCA only 390 54%
LCx & RCA only 332 52%
LAD & LCx & RCA 470 61%
LAD Disease No 358 52% 0.05 0.03
Yes/ None Attempted 213 62%
Yes/ ≥ 1 Attempted 1035 58%
LCx Disease No 408 54% 0.38 0.21
Yes/ None Attempted 268 59%
Yes/ ≥ 1 Attempted 930 57%
Proximal Disease No 516 56% 0.75 0.49
Yes/ None Attempted 167 56%
Yes/ ≥ 1 Attempted 923 58%
Proximal LAD Disease No 1033 55% 0.06 0.02
Yes/ None Attempted 80 61%
Yes/ ≥ 1 Attempted 493 61%
Any Total Occlusions No 1048 58% 0.24 0.28
Yes/ None Attempted 380 53%
Yes/ ≥ 1 Attempted 178 59%
Any Diffuse Lesions No 1169 56% 0.26 0.10
Yes/ None Attempted 424 60%
Yes/ ≥ 1 Attempted 13 62%
Angiographic Success Partial 161 60% 0.45
Total 1443 57%
Incomplete Revascularization No 615 54% 0.13
Yes 991 58%
0 615 54% 0.47
1 578 59%
2 275 57%
3+ 138 57%
Row percentages are presented.
* Chi-square test p-value compares the presented categories;  † Chi-square test p-value compares presence 
versus absence of the lesion characteristic;  ‡ Cochran-Armitage trend test p<0.01.
P-      
value*
P-      
value†
No. of Significant Lesions 
Remaining
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Table 4.3  Cox model estimates for the first repeat revascularization event 
 
Adjusted 
RR 95% CI P-value
Male 1.44 1.23 - 1.69 <0.001
Diabetes 1.46 1.24 - 1.73 <0.001
Renal dysfunction 1.51 0.97 - 2.36 0.07
Age ≥ 65 years 0.82 0.71 - 0.94 <0.01
Smoking history 0.70 0.61 - 0.81 <0.001
ST elevation 0.47 0.31 - 0.71 <0.001
Unstable angina 1.16 1.02 - 1.32 0.03
Proximal LAD disease 1.25 1.09 - 1.42 <0.01
Diffuse disease 1.18 1.02 - 1.37 0.02
Incomplete revascularization 1.13 0.99 - 1.30 0.07
RR indicates relative risk;  CI confidence interval
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 Table 4.4  PWP model estimates for multiple repeat revascularization events 
 
Event       
Number RR   (95% CI) P-value
P-value* for 
Equal Assoc
1 1.44  (1.23-1.69) <0.001
2 1.00  (0.78-1.28) 0.97
3 0.64  (0.45-0.91) 0.01
Diabetes 1.43  (1.25-1.64) <0.001 -
Renal dysfunction 1.75  (1.27-2.41) <0.001 -
Age ≥ 65 years 0.84  (0.75-0.94) <0.01 -
1 0.71  (0.61-0.81) <0.001
2 and 3 0.96  (0.79-1.15) 0.63
ST elevation 0.52  (0.37-0.74) <0.001 -
Unstable angina 1.15  (1.04-1.28) 0.01 -
1 1.24  (1.09-1.42) <0.01
2 and 3 0.95  (0.79-1.14) 0.58
Diffuse disease 1.13  (1.01-1.27) 0.03 -
1 1.13  (0.99-1.30) 0.07
2 and 3 0.86  (0.72-1.03) 0.09
PWP indicates Prentice-Williams-Peterson;  RR relative risk;  CI confidence interval
Male <0.001
*   P-value tests the null hypothesis that the respective predictor has the same impact on all repeat 
revascularization events.
Smoking history 0.01
Proximal LAD disease 0.02
Incomplete Revascularization 0.01
 
 
  63
5.0  FACTORS RELATED TO SELECTION OF CABG VERSUS PCI IN PATIENTS WITH 
DIABETES AND STABLE MULTIVESSEL DISEASE IN BARI 2D 
  Lauren J. Kim, MPH;*  Kevin E. Kip, PhD;*  Oscar C. Marroquin, MD;†  Sheryl F. Kelsey, PhD;*
 
           Francesmary Modugno, PhD;*  Frederick Feit, MD;‡  and Maria Mori Brooks, PhD*
 
                                                        for the BARI 2D Investigators  
 
        *   Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania   
 
†   Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
 
                   ‡   New York University School of Medicine, New York, New York  
 
 
 
 
 
 
(This manuscript has not yet been submitted for publication)  
  64
5.1 INTRODUCTION 
Patients with type 2 diabetes represent approximately 25% of the 1.5 million coronary revascularizations 
performed annually in the United States.1-4  Diabetic patients, compared to those without diabetes, 
experience worse short- and long-term outcomes after both coronary artery bypass graft (CABG) surgery 
and percutaneous coronary intervention (PCI);4-6 hence, trying to determine which is the more appropriate 
strategy in diabetic patients requiring coronary revascularization is a complex issue.  The original BARI 
trial was instrumental in shedding light on the issue in reporting a significantly lower long-term mortality 
in patients with diabetes and multivessel disease who underwent initial revascularization with CABG 
versus balloon-only PCI.7  Similarly, the benefit of CABG was greater in patients with more extensive 
coronary disease.8  These findings, particularly the former, prompted the National Heart, Lung, and Blood 
Institute (NHLBI) to issue a Clinical Alert recommending CABG over balloon angioplasty in patients 
with treated diabetes and multivessel CAD.9  
 In the years since BARI results were first reported, advances in PCI technology and adjunctive 
therapy have significantly improved peri-procedural and short-term outcomes.  Use of glycoprotein (Gp) 
IIb/IIIa receptor inhibitors10, 11 and drug-eluting stents,12-15 in particular, have significantly decreased the 
rate of restenosis and other indications of early failure, and also improved short-term survival.  In 
addition, there has been an increasing appreciation for the critical role of intensive medical management 
of atherosclerosis.  Aggressive glycemic control,16-18 lipid-lowering agents,19, 20 beta-blockers,21 and ACE 
inhibitors22 have been shown to significantly lower cardiovascular events and mortality, and long-term 
use has become standard for patients undergoing coronary revascularization.  These developments have 
overcome some of the main limitations of traditional balloon angioplasty, including: high incidence of 
restenosis,23 inability to achieve a more complete revascularization,24 and accelerated progression of 
atherosclerosis.25-27  Although data from randomized trials and long-term studies are not yet available, 
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current trends indicate that these improvements may offset the advantage of CABG over PCI among 
patients with diabetes and multivessel CAD.   
 The current ACC/AHA guidelines on coronary revascularization are generally based on CAD 
severity, coronary anatomy and lesion morphology, as well as patient risk factors such as age.28, 29  For 
patients with diabetes, CABG is preferred over PCI in the presence of left main disease, multivessel CAD 
involving the proximal left anterior descending (LAD) artery and moderate to severe symptoms.  
Although there are no clear recommendations for less severe indications, CABG is considered the 
standard treatment for non-selected patients with diabetes and multivessel disease.26  Introduction of 
intracoronary stents and other developments have not changed recommendations for patients with either 
mild or very severe CAD; individuals with limited disease are generally treated with PCI and those with 
extensive disease are referred for CABG.  But for the subset of patients with diabetes and stable 
multivessel disease whose risk profiles fall somewhere in between these ends of the spectrum, the 
decision is less straightforward.  In the absence of compelling evidence to choose one revascularization 
treatment over another, clinicians make a judgment based on multiple patient-specific factors including: 
(i) anticipated feasibility of PCI to successfully dilate ischemia-producing lesions; (ii) prior medical 
history that may impact clinical outcome; and (iii) patient preference.  While this global patient-specific 
assessment may appear straightforward, it is noteworthy that significant regional (i.e. geographic) 
differences in the treatment of ischemic heart disease have been previously described,30-32 indicating that 
both patient-level and contextual (e.g. geographic region, clinical center) factors guide treatment 
decisions.  This ambiguity exists among patients with diabetes and stable CAD where there is little 
consensus regarding the optimal method of revascularization, and factors influencing this decision are 
poorly understood.   
 Therefore, the purpose of this study was to investigate factors associated with the decision to 
perform CABG versus PCI in patients with diabetes and stable multivessel disease in the Bypass 
Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.  An important feature of this 
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analysis was to describe how much of this decision-making process is driven by geographic region alone, 
independent of individual patient-level factors.   
5.2 METHODS 
5.2.1 Study Design 
BARI 2D is a randomized clinical trial designed to simultaneously compare 2 treatment strategies in 
patients with type 2 diabetes and stable CAD: (i) coronary revascularization plus aggressive medical 
therapy versus aggressive medical therapy alone with the option for delayed revascularization for 
treatment of CAD; and (ii) an insulin-providing strategy versus insulin-sensitizing strategy for treatment 
of diabetes.  A detailed description of the study has been published previously.33  In brief, eligibility 
criteria included angiographically documented CAD involving at least one coronary vessel (≥50% 
stenosis) suitable for treatment with either medical therapy alone or elective revascularization by either 
CABG or PCI.  Patients requiring coronary revascularization for prompt relief of symptoms were not 
eligible.  Exclusion criteria included severe left main disease and prior CABG or PCI in the past 12 
months.  Participants were enrolled from 49 clinical sites in the United States, Canada, Czech Republic, 
Austria, Brazil, and Mexico from January 1, 2001 until March 31, 2005.   
 Although patients were randomly assigned to either immediate coronary revascularization plus 
intensive medical therapy or intensive medical therapy alone, selection of the revascularization strategy 
was at the discretion of the treating physicians.  Moreover, all patients were evaluated to determine 
suitability for CABG or PCI, and prior to randomization, clinicians declared the intention to perform 
either CABG or PCI if the patient were ultimately randomized to the invasive intervention arm.  In the 
present analysis, we were primarily interested in factors related to the decision to perform CABG (versus 
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PCI).  Therefore, CABG and PCI revascularization strategies indicate the treatment that was intended 
prior to randomization, and not treatment that was ultimately received. 
 Baseline angiographic data were assessed locally by the clinical sites as well as a centralized core 
laboratory (Stanford University).  Since clinicians based patient eligibility and the CABG versus PCI 
decision on site (non-core) evaluations, we first considered the use of angiographic data based on site 
interpretation.  However, because only limited angiographic data were recorded by clinical sites on the 
case report forms, we secondarily used angiographic variables from the core lab that were not recorded by 
site evaluations, under the assumption that these characteristics were recognized and considered by 
clinicians during the initial evaluation.  Patients with ≥80% missing baseline data were excluded from the 
overall analysis (n=47).   
 The myocardial jeopardy index (MJI) was a core laboratory measurement which reflects 
percentage of the myocardium that was jeopardized by significant lesions at baseline.34  Because MJI did 
not take into account previously revascularized lesions that were patent, it did not reflect cumulative 
burden of coronary disease.  Therefore, patients with prior PCI (n=285) were excluded in the presentation 
of MJI data.   
 Our primary interest was to evaluate factors related to the selection of CABG over PCI in 
moderate to high-risk patients with diabetes and stable CAD, for whom there is little consensus regarding 
optimal treatment.  Since this decision is inherently biased toward PCI in patients who have previously 
undergone CABG, we excluded this subset (n=149).  At the other extreme, patients with stable single 
vessel CAD, irrespective of the presence or absence of diabetes, are usually referred for PCI; therefore, 
this subgroup was also excluded from the analysis (n=601).  By virtue of these selection criteria, which 
limited the analysis to patients with diabetes and multivessel CAD, this gave us an opportunity to 
indirectly evaluate the impact of the original BARI results on contemporary practice, a decade after the 
NHLBI issued a Clinical Alert regarding the superiority of CABG over balloon angioplasty in this patient 
population.   
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5.2.2 Statistical Methods 
We started the analysis by examining selection of revascularization strategy by geographical region 
irrespective of patient characteristics.  Although the percentage of CABG-intended patients varied across 
countries outside of the US (e.g. Canada versus Brazil), US versus non-US regions provided the most 
informative comparison, given the wide range in the numbers of patients within sites and sites within 
regions.  Patient characteristics related to the decision to perform CABG were then assessed separately for 
US and non-US regions.  Baseline clinical and angiographic characteristics were compared using the Chi-
square test for categorical variables and the Cochran-Armitage trend test for ordinal variables.   
 Since patients were nested in clinical sites, and sites were nested in regions, we assessed the 
degree of correlation in treatment selection within and between individual clinical sites by fitting 
covariance patterns (residuals) using generalized estimating equations (GEE).35  Preliminary analyses 
revealed considerable amount of correlation in our data, and we decided that multilevel modeling using 
GEE was the appropriate statistical procedure for multivariable analysis, which accounts for correlation 
and provides more accurate error estimates, resulting in p-values and confidence intervals that are 
unbiased with respect to correlation.36  However, since our GEE modeling software did not support a 
forward selection procedure, the multivariable model was initially built using standard logistic 
regression,37 ignoring clustering in our data.  We expected this to result in erroneously low p-values, and 
therefore, a p-value cutoff of 0.01 was applied throughout the model-building procedure.  In the final step, 
data were re-fitted using GEE.   
 Patient characteristics associated with the decision to perform CABG were identified using 
logistic regression by running 4 separate forward selections, one for each category of baseline variables: 
clinical, baseline medications, site angiographic data, and core lab angiographic data.  We fitted a final 
forward selection procedure with patient-level characteristics identified in the previous steps as candidate 
variables.  Region, a higher-level predictor, was then added to the model.  In order to avoid imprecise 
estimates, we combined Canada and Europe, and also Brazil and Mexico, on the basis of similarities in 
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health care delivery systems as well as percentage of CABG-intended patients observed in this study.  
Therefore, geographic region was included in the final model as a 3-level variable (Canada and Europe; 
and Brazil and Mexico versus US).  Variables with p>0.01 were subsequently removed using backward 
selection, and variables remaining in the model were assessed for multiple collinearity.  Statistical 
interactions were initially tested between US (versus non-US) region and each variable in the main effects 
model.  Any interaction terms with p<0.01 were tested in a second model with region as a 3-level 
variable, and only interactions with p<0.01 were retained in the final model.  In the last step of the 
multivariable analysis, the data were refitted using GEE which accounted for between- and within-site 
correlations.   
 Missing values (<1% of values) for covariates included in the final multivariate model were set to 
zero for binary variables; thus, dichotomous covariates may be interpreted as the known presence of the 
respective characteristic.  Estimates for odds ratios (OR), 95% confidence intervals (CI), and p-values are 
reported, and P<0.05 are considered statistically significant.  All statistical analyses were performed using 
SAS 9.1 (Cary, NC).   
5.3 RESULTS 
5.3.1 Regional Variation in the Decision to Perform CABG versus PCI 
Of the 2368 patients with diabetes enrolled in the BARI 2D trial, 1592 with multivessel disease and no 
prior history of CABG were included in this analysis.  Patients were enrolled across 40 clinical sites in the 
US (n=910) and 9 sites in other parts of the world (n=682).  As seen in Table 1.1, the decision to perform 
CABG versus PCI was made twice as often in patients seen outside of the US compared to those in the 
US (61% vs. 31%, P<0.001).  The percentage of CABG-intended patients in regions outside of the US 
ranged from 47% in Canada, 56% in Europe, 73% in Brazil, and 76% in Mexico.  Selection of 
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revascularization strategy differed significantly across the 5 geographic regions (P<0.001).  GEE 
covariance estimates indicated that 29% of the variation in treatment decision was explained by US vs. 
non-US sites irrespective of patient characteristics; further distinguishing between the 4 non-US regions 
explained a slightly higher 34% of the variation.   
 To assess whether the substantial geographic variability in selection of revascularization strategy 
was due simply to patient differences in CAD severity between regions, we compared the percentage of 
CABG-intended patients across increasing levels of the myocardial jeopardy index (MJI) within- and 
outside of the US (Figure 5.1).   
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Figure 5.1  Intention to perform CABG within myocardial jeopardy quartiles in US and 
non-US sites 
 
In both regions, the decision to perform CABG increased as disease burden increased, but within each 
MJI quartile, patients in the US were much less likely to be referred for surgical treatment compared to 
those in other countries (P<0.001).   
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Figure 5.2  Variation across clinical sites in the percentage of CABG-intended patients by 
median myocardial jeopardy index 
 
 Geographic region alone, however, did not explain all of the discordance.  As seen in Figure 5.2, 
the median patient MJI at each clinical site was associated with the percentage of CABG-intended 
patients at each site (correlation coefficient R=0.53), yet there remained substantial variability in the 
decision to perform CABG across BARI 2D sites in both regions and at low and high levels of MJI.  
Among clinical sites with 10 or more patients, the percentage of CABG-intended patients varied from 0% 
to 74%, and notably, there were 3 sites (2 US and 1 non-US) in which no patients were recommended for 
CABG irrespective of the percentage of jeopardized myocardium.   
 We considered that this decision making process, particularly the US versus non-US variation, 
may have been influenced by factors related to the clinical sites per se rather than characteristics of 
individual patients.  Unfortunately, very limited site-level data were collected in BARI 2D, including the 
ratio of surgeons to PCI operators, availability of off-pump surgery, and whether or not conduits other 
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than internal mammary artery and saphenous vein grafts (or ‘alternate conduits’) were used.  Assessment 
of these site-specific characteristics as possible predictors of the treatment decision indicated minimal to 
no influence (data not shown).   
5.3.2 Patient Characteristics Associated with CABG Selection  
Patient characteristics related to intended revascularization with CABG (versus PCI) are presented in 
Table 5.2 for all patients, and separately for those in US and non-US regions.  In the overall cohort, 
patients who were Hispanic or white (race), without a prior PCI and not taking anti-platelet agents at 
baseline were more likely to be recommended for CABG.  In the US, patients who were male, age 65 
years and older, and without a history of stroke or transient ischemic attacks were more likely to be 
deemed most suitable for surgical revascularization.  These factors did not influence treatment selection 
outside of the US.  Instead, demographic and clinical characteristics in non US regions that were 
associated with the decision to perform CABG included lower education, prior MI, and hypertension.   
 Angiographic characteristics associated with the decision to perform CABG are presented in 
Table 5.3.  The prevalence of triple vessel disease was 53% overall, and nominally lower in the US 
compared to other regions (50% vs. 57%, respectively).  Overall, angiographic factors related to treatment 
selection were consistent across US and non-US regions.  Diabetic patients with triple (versus double) 
vessel disease were more likely to be recommended for CABG (p<0.001).  Other angiographic 
characteristics associated with intended surgical revascularization included: number of vessels with ≥70% 
stenosis, increasing MJI, significant (≥50%) LAD and proximal LAD disease, presence of total occlusions 
and non-discrete lesions, and total number of lesions (irrespective of severity).  Increasing number of 
class C lesions and significant lesions (≥50% or ≥70% stenosis), particularly those involving a proximal 
segment, were also associated with an increased likelihood of intended treatment with CABG.  One 
angiographic factor that differed in its predictive value between the two regions was depressed left 
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ventricular function.  Despite a very low prevalence of 5% in the overall cohort, ejection fraction <40% 
was related to recommendation for CABG in the US but not in non-US regions.   
5.3.3 Multivariable Analysis Results 
Adjusted odds of the intention to perform CABG versus PCI estimated using GEE are presented in Table 
5.4.  Among patients with diabetes and multivessel disease, angiographic characteristics indicating extent 
and severity of CAD were highly predictive of recommendation for CABG over PCI.  The odds of 
selecting CABG was significantly higher among patients with triple (vs. double) vessel disease 
(OR=3.64, 95% CI 2.85-4.64; p<0.001) and presence (vs. absence) of proximal LAD stenosis ≥50% 
(OR=1.80, 95% CI 1.15-2.80; p=0.01), LAD stenosis ≥70% (OR=2.46, 95% CI 1.96-3.09; p<0.001), total 
occlusions (OR=1.78, 95% CI 1.30-2.44; p<0.001), and increasing number of class C lesions (OR=1.61, 
2.13, and 3.62 for 1, 2, and 3+ lesions (vs. 0); all p<0.001).  Several demographic and clinical factors 
were also predictive of treatment selection.  The odds of selecting CABG over PCI was significantly 
higher in men (OR=1.25, 95% CI 1.03-1.51; p=0.02) and patients >65 years old (OR=1.38, 95% CI 1.11-
1.73; p<0.01).  Patients who had undergone prior PCI and those using antiplatelet agents were less likely 
to be recommended for CABG (OR=0.50, 95% CI 0.39-0.64, p<0.001; and OR=0.68, 95% CI 0.50-0.92, 
p=0.01, respectively).  Independent of patient characteristics, this decision making process was 
significantly influenced by geographic region.  Compared to the US, the odds of selecting CABG was 
significantly higher among patients seen in Canada and Europe (OR=1.81, 95% CI 1.03-3.20; p=0.04) 
and more than 4-times higher in Brazil and Mexico (OR=4.71, 95% CI 3.23-6.87; p<0.001).   
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5.4 DISCUSSION 
In the present study, we evaluated factors influencing the selection of coronary revascularization strategy 
in patients with diabetes and stable multivessel disease in the BARI 2D trial.  As expected, the decision to 
perform CABG over PCI was driven largely by angiographic features, reflecting existing limitations of 
PCI under certain anatomic circumstances, such as severe 3-vessel disease and total occlusions.  
Moreover, several angiographic characteristics that were closely related were independently predictive of 
treatment selection, suggesting that patient’s anatomy is considered in aggregate in the treatment decision.  
For example, on average, patients with a total occlusion and a class C lesion are more likely to be 
recommended for CABG than patients with a single total occlusion alone.   
 In addition, several non-angiographic characteristics influenced treatment selection.  In BARI 2D, 
men were more likely to be referred for CABG.  It is well-recognized that women undergoing surgical 
revascularization experience worse perioperative outcomes compared to men,38-41 and female gender has 
been identified as an independent risk factor in both the Society for Thoracic Surgeons risk modeling42 
and the EuroSCORE risk algorithm.43  Clinicians may have taken this into consideration when deciding 
on treatment strategy.  We also found that older age was associated with CABG selection.  Although 
previous studies have shown old age to be a deterrent against surgical revascularization, BARI 2D has an 
inclusion criteria of 5-year expected survival and stable presenting clinical status; hence, age was 
apparently not judged to be a contra-indication to bypass surgery in this trial.   
 Patients who had undergone prior PCI and those using antiplatelet agents at baseline were less 
likely to be recommended for CABG.  Per BARI 2D inclusion criteria, any previous revascularizations 
had to be at least one year prior to study enrollment, indicating that the most recent PCI was most likely 
initially successful without immediate need for re-intervention.  In these patients, it is possible that 
clinicians and patients would be inclined to attempt PCI again.  As for current patient use of antiplatelet 
agents, physician concern over an increased risk of perioperative bleeding is a possible explanation for 
selecting the less invasive percutaneous approach. 
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 Importantly, not all factors influencing this decision-making process were features unique to 
individual patients, but rather, simply the individual clinical centers and geographic regions where 
patients were seen.  Patients seen in countries outside of the US were much more likely to be selected for 
CABG compared to US patients even after taking into account differences in presenting profiles and 
disease severity.  By covariance estimation, about one-third of the treatment decision process was made 
simply by the geographic region in which patients were seen.  Moreover, even within individual regions, 
there were clear site differences in the preference for recommending CABG over PCI.  These findings 
illustrate that in the absence of firm, unequivocal treatment guidelines, physician discretion plays a large 
role in determining patient revascularization treatment, and that factors (unidentified) associated with 
clinical centers and geographic regions augment, and possibly override, individual patient characteristics 
when there is no obvious clinical advantage for CABG over PCI.          
5.4.1 Possible Explanations for Geographic Variation in Treatment Selection 
Despite our in-depth multivariable analysis, it remains possible that regional variation in the decision to 
perform CABG over PCI can be explained primarily by intrinsic differences in patient risk profiles.  
Patients in the US (compared to those in other countries) did have, on average, less severe CAD and were 
slightly older and more educated, all of which seemingly influenced the more frequent recommendation 
for the less invasive and lower risk PCI.  However, on the basis of our extensive individual-level dataset, 
differences in the distribution of the patient characteristics alone between US and non-US regions did not 
fully explain the variation in treatment decision.  The greater reluctance to perform CABG in the US was 
demonstrated at every level of disease burden, and even after adjusting for patient characteristics and 
accounting for correlation within sites, region remained a strong independent predictor of treatment 
selection.  Thus, we conclude that it is unlikely that the substantial influence of individual clinical center 
and geographic region on the selection of revascularization strategy is confounded by individual patient 
factors that were either not measured or controlled for in our analysis. 
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 How might characteristics of the clinical centers and regions have played an influential role in the 
treatment decision of CABG versus PCI?  First, differential access to invasive cardiac procedures outside 
of a research setting (such as BARI 2D) may be a factor.  Previous studies have attributed the higher 
number of cardiac procedures performed in the US (compared to other countries) to greater availability of 
these procedures in the US.30, 32  Given the potential for less, or delayed, accessibility to interventional 
procedures outside of the US (e.g. repeat procedures), we can speculate a predisposition toward 
recommending CABG, the more durable procedure, at centers outside of the US.  This may be 
particularly likely given the higher rates of repeat revascularizations, primarily to treat target-vessel 
restenosis, among patients with diabetes following PCI.44 
 It is also possible that our observed site and regional variation in recommending CABG versus 
PCI was driven by unique characteristics of individual clinical centers, rather than geographic region per 
se.  However, in BARI 2D, participating clinical sites had to meet minimal study-specific certification 
requirements for both PCI and CABG, including annual case volume.  Thus, all participating centers were 
fully proficient in performing PCI and CABG.  Moreover, among the few site-level variables collected, 
including the ratio of CABG surgeons to PCI operators, we found no association of such factors with 
treatment selection.  Thus, there were no readily identifiable factors specific to individual clinical centers 
that appeared to influence treatment selection.  Nonetheless, we cannot exclude unmeasured clinical and 
“corporate” climate, as well as financial considerations of individual hospitals, as being influential in the 
revascularization selection process.  
 Because the original BARI trial pre-dated the use of drug-eluting stents, Gp IIb/IIIa inhibitors, 
and other advances in coronary intervention, its recommendation for CABG over conventional balloon 
angioplasty in diabetic patients may have limited applicability to contemporary practice.  McGuire and 
colleagues evaluated the influence of BARI results on practice patterns in the US two years after the 
Clinical Alert was issued.45  They reported significant variability in revascularization strategy used to treat 
patients with diabetes and multivessel CAD and concluded that the original BARI results did not have an 
impact on practice patterns in the US.  Nearly 10 years later, we find in the BARI 2D trial that there is 
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still little consensus regarding the most appropriate method of revascularization in diabetic patients with 
stable multivessel disease.  We will look to the FREEDOM trial to help elucidate the optimal 
revascularization strategy in this high-risk population.   
5.4.2 Study Limitations 
Two issues may limit the generalizeability of our results.  First, enrollment in the BARI 2D trial occurred 
as the first generation of drug eluting stents was introduced.  Current trends demonstrate that indications 
for percutaneous intervention with DES have expanded to include patients who, historically, would have 
been treated with bypass surgery.  This decision-making process continues to evolve since BARI 2D 
started, which may limit the relevance of our findings.  Second, participating clinical sites in this trial are 
established centers of excellence that deliver quality medical care both in and outside of the US.  As a 
result, practice patterns in these centers may not reflect general practice, which often include smaller 
community-based hospitals.  In addition, our investigators and patients from Brazil and Mexico were 
from a single center, and it is unclear how representative these particular sites are of their respective 
countries at large.  However, since the choice of revascularization strategy was at the discretion of local 
physicians, the decision to perform CABG observed in BARI 2D study centers likely reflect usual 
practice in these particular centers.   
5.5 CONCLUSION 
Among patients with diabetes and stable multivessel CAD in the BARI 2D trial, the decision to perform 
CABG over PCI was related to angiographic features associated with extent, location, and nature of CAD, 
as well as demographic and clinical factors.  However, patient characteristics were not absolute in 
determining the method of revascularization.  Treatment selection was also influenced by geographic 
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region, with a greater propensity to recommend PCI in the US.  There was substantial variation in 
treatment selection across geographic regions, and among clinical sites within regions, indicating that 
physician discretion plays an important role in this decision making process. 
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 Table 5.1 Intended revascularization strategy by geographic region 
 
n Row % n Row %
US 40 910 283 31% 627 69% <.001 *
Non-US 9 682 419 61% 263 39%
Canada 5 271 128 47% 143 53% <.001 †
Europe 2 57 32 56% 25 44%
Brazil 1 292 212 73% 80 27%
Mexico 1 62 47 76% 15 24%
Total 49 1592 702 44% 890 56%
Row percentages are presented.
Excludes patients with prior CABG (n=149) and single vessel disease (n=601)
*  Chi-square p-value compares treatment selection in US versus non-US regions.
†   Chi-square p-value compares treatment selection across the 5 regions.
CABG PCINo. of 
Sites
No. of 
Patients
P -       
value
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 Table 5.2  Baseline characteristics associated with intention to perform CABG (versus PCI) 
 
No. of 
Patients
Intended 
CABG P* n
Intended 
CABG P* n
Intended 
CABG P*
DEMOGRAPHIC PROFILE
Sex Male 1149 46% <.01 640 34% <.01 509 62% 0.68
Female 443 38% 270 24% 173 60%
Age < 65 y/o 949 42% 0.06 514 27% <.01 435 60% 0.31
≥ 65 y/o 643 47% 396 36% 247 64%
Race White (non-Hisp) 1054 47% <.001 533 33% 0.04 521 61% <.01
Black (non-Hisp) 251 31% 208 24% 43 67%
Hispanic 198 48% 134 36% 64 75%
Other 89 36% 35 26% 54 43%
≥ High School educ No 619 55% <.001 224 31% 0.90 395 68% <.001
Yes 968 37% 682 31% 286 52%
Health insurance Public 1155 49% <.001 519 33% 0.26 636 61% 0.03
Private 368 32% 330 28% 38 68%
None/ Self pay 67 27% 60 28% 7 14%
CLINICAL HISTORY
Prior MI No 1065 41% <.01 641 30% 0.35 424 58% 0.02
Yes 501 50% 255 33% 246 67%
Prior PCI No 1306 47% <.001 713 34% <.001 593 63% 0.01
Yes 285 29% 196 20% 89 48%
Anti-platelet agent use No 1304 47% <.001 705 34% <.001 599 63% 0.09
Yes 285 30% 204 21% 81 53%
Current insulin use No 1170 47% <.001 617 33% 0.06 553 62% 0.65
Yes 422 37% 293 27% 129 60%
Hypertension No 271 41% 0.26 139 31% 0.97 132 52% 0.01
Yes 1300 45% 766 31% 534 64%
Stroke/ TIA No 1425 45% 0.01 794 32% 0.02 631 61% 0.64
Yes 160 34% 112 21% 48 65%
Angina status No angina 290 41% 0.09 170 29% 0.44 120 59% 0.15
Atypical angina 348 43% 227 35% 121 57%
Stable class I/II 683 46% 336 32% 347 61%
Stable class III/IV 139 50% 69 29% 70 70%
Unstable angina 132 36% 108 26% 24 79%
Row percentages are presented.
*  Chi-square test p-values compare percentage of CABG-intended patients for groups defined by the variables 
listed
All Sites  (N=1592) US  (n=910) Non-US  (n=682)
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Table 5.3  Angiographic characteristics associated with intention to perform CABG (versus PCI) 
 
No. of 
Patients
Intended 
CABG P* n
Intended 
CABG P* n
Intended 
CABG P*
Clinical Site Measurements
Vessel disease Double 745 25% <.001 453 16% <.001 292 40% <.001
Triple 847 61% 457 46% 390 77%
LAD ≥ 50% stenosis No 202 17% <.001 130 11% <.001 72 29% <.001
Yes 1390 48% 780 34% 610 65%
No. of vessels w/ ≥ 70% 0 44 11% <.001 32 0% <.001 12 42% <.001
stenosis † 1 366 22% 242 14% 124 39%
2 712 39% 408 28% 304 53%
3 470 72% 228 59% 242 85%
LAD ≥ 70% stenosis No 510 24% <.001 334 16% <.001 176 39% <.001
Yes 1082 54% 576 40% 506 69%
Any total occlusions No 1015 34% <.001 632 23% <.001 383 52% <.001
Yes 577 62% 278 49% 299 74%
Ejection fraction < 40% ‡ No 1424 45% 0.47 794 30% <.01 630 63% 0.55
Yes 82 49% 64 47% 18 56%
Core Lab Measurements
Myocardial jeopardy †§ ≤ 25% 158 18% <.001 110 11% <.001 48 33% <.001
26-50% 443 34% 262 22% 181 51%
51-75% 467 58% 242 45% 225 71%
76-100% 238 72% 99 65% 139 78%
Total number of lesions † ≤ 3 301 26% <.001 173 13% <.001 128 43% <.001
4 325 38% 185 23% 140 57%
5 303 46% 175 31% 128 66%
6 248 49% 137 38% 111 63%
≥ 7 414 58% 239 46% 175 74%
No. of lesions ≥ 50% † ≤ 1 272 17% <.001 191 8% <.001 81 37% <.001
2 401 33% 224 25% 177 44%
3 377 49% 213 34% 164 68%
≥ 4 541 62% 281 49% 260 77%
Proximal LAD ≥ 50% No 1363 41% <.001 799 28% <.001 564 59% 0.01
Yes 228 62% 110 52% 118 72%
No. of Proximal lesions 0 622 34% <.001 373 20% <.001 249 54% <.001
 ≥ 50% † 1 660 45% 371 32% 289 61%
2+ 309 63% 165 53% 144 75%
No. of Class C lesions † 0 678 29% <.001 435 20% <.001 243 45% <.001
1 567 50% 304 39% 263 64%
2 221 63% 109 50% 112 77%
3+ 106 76% 44 59% 62 89%
Any non-discrete lesions No 781 39% <.001 452 25% <.001 329 58% 0.06
Yes 791 50% 440 38% 351 65%
Row percentages are presented.
* Chi-square p-values compare percentage of CABG-intended patients for groups defined by variables listed;  † Cochran-
Armitage trend test P <0.05;  ‡ Ejection fraction missing for 86 patients;  § Excludes patients with prior PCI (n=285)
All Sites  (N=1592) US  (n=910) Non-US  (n=682)
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 Table 5.4 GEE model for predictors of intended revascularization with CABG 
(versus PCI) 
Adjusted 
OR 95% CI P -value
Geographic Region <0.01
Canada & Europe (vs. US) 1.81 1.03 - 3.20
Brazil & Mexico  (vs. US) 4.71 3.23 - 6.87
Male gender 1.25 1.03 - 1.51 0.02
Age ≥ 65 years 1.38 1.11 - 1.73 <0.01
Prior PCI 0.50 0.39 - 0.64 <0.001
Use of anti-platelet agents 0.68 0.50 - 0.92 0.01
Triple vessel disease 3.64 2.85 - 4.64 <0.001
Proximal LAD ≥ 50% stenosis * 1.80 1.15 - 2.80 0.01
LAD ≥ 70% stenosis 2.46 1.96 - 3.09 <0.001
Any total occlusions 1.78 1.30 - 2.44 <0.001
No. of class C lesions * <0.01
1    (vs. 0) 1.61 1.22 - 2.14 <0.001
2    (vs. 0) 2.13 1.37 - 3.32 <0.001
3+  (vs. 0) 3.62 1.77 - 7.41 <0.001
OR indicates odds ratio; CI confidence interval.
*  Indicates core lab measurement; all other angiographic variables were based 
on site evaluation.  
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6.0  GENERAL DISCUSSION 
6.1 SUMMARY OF FINDINGS 
The objective of this dissertation was to evaluate myocardial revascularization in patients with 
multivessel coronary disease.  Contemporary statistical methods were applied to investigate predictors of 
long-term prognosis and factors related to selection of revascularization strategy in the BARI and BARI 
2D cohorts, respectively. 
 In Research Paper 1, treatment with CABG had a different effect on specific causes of death.  
Specifically, CABG was associated with a lower risk of sudden cardiac death, but did not significantly 
impact any other causes of long-term mortality.  Moreover, the protective effect of surgical treatment was 
observed in patients with and those without diabetes.  These results may have clinical implications for 
guiding revascularization strategy in individuals at high risk of sudden death.  In this select group of 
patients, CABG may be the preferred method of initial revascularization.   
 Research Paper 2 evaluated the need for additional procedures following successful initial 
balloon angioplasty.  In BARI, male gender, proximal LAD disease, and incomplete revascularization 
were associated with a significantly increased risk of a first repeat revascularization but not latter events.  
This may be explained by a higher likelihood, among patients with these characteristics, to receive CABG 
as the first subsequent treatment.  Diabetes and extensive coronary disease were also predictive of a first 
repeat revascularization event, but the detrimental impact of these factors on the number of recurrent 
procedures remained consistent over time, underscoring the importance of intensive risk factor 
modification to limit disease progression. 
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 In Research Paper 3, angiographic features associated with the extent and location of coronary 
disease greatly influenced the decision to perform CABG over PCI in patients with diabetes and stable 
multivessel disease.  Gender, age, prior PCI, and use of anti-platelet agents at baseline also played a role 
in treatment selection.  However, this decision making process was not entirely based on patient factors; 
geographic region also played an important role, with a greater propensity to recommend PCI in the US 
compared to other countries of origin.  We also found that selection of revascularization strategy in varies 
substantially across individual clinical sites.  These results demonstrate the need for rigorous evaluation 
of revascularization strategy in diabetic patients and other select high-risk subgroups and the factors that 
guide this decision making process in current practice.   
6.2 IMPACT OF DIABETES ON LONG-TERM PROGNOSIS 
Although diabetes was not the main focus of any of the papers, it turned out to be an important finding in 
both long-term evaluations of the BARI cohort.  In Research Paper 1, diabetes was shown to be a 
powerful, independent predictor of overall mortality and each specific cause of death in patients with 
multivessel disease undergoing initial revascularization.  Percutaneous intervention studies have 
consistently reported higher rates of subsequent revascularization in patients with, compared to those 
without, diabetes.  Research Paper 2 extended these previous findings by demonstrating a persisting 
effect of diabetes on the increasing number of additional procedures.  Even after statistically adjusting for 
other confounding factors, diabetes was associated with an estimated 43% increase in the rate of 
subsequent revascularization over 10 years after initial PCI;  in a ‘lower risk’ subgroup that was less 
subject to survival and selection bias, the risk increase was an estimated 74%.  Overall, these results 
support prior studies demonstrating worse long-term prognosis for diabetic patients following coronary 
revascularization.   
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6.3 UTILITY OF CONTEMPORARY STATISTICAL PROCEDURES 
Among clinical researchers, the importance of study design and methodological issues that may lead to 
bias are widely understood.  This is one of the reasons BARI has been well received and cited in medical 
literature, and results from BARI 2D are anticipated.  What is not as widely or uniformly appreciated is 
the important role of rigorous and appropriate statistical analyses.  Conclusions drawn from a study are 
only as good as the quality of the data and the inferential procedures that are applied to them.  The 
application of contemporary, computationally-intensive statistical methods in this dissertation illustrate 
what can be gained by exploring new ways of looking at data, and also the importance of applying the 
appropriate methods. 
 Multiple events modeling proved to be especially useful in the evaluation of long-term outcomes.  
Since cardiovascular disease is a progressive, life-long disease with multi-factorial etiology and 
concomitant risk factors, CVD trials often have long follow-up periods during which participants may 
experience various number and types of clinical events.  Application of WLW and PWP regression 
allowed us to evaluate the incremental effect of risk factors (i.e. diabetes) and recurrence of adverse 
events (i.e. repeat procedures) as measures of increasing disease burden.  As a result, we were able to gain 
new insights into the BARI cohort.  Furthermore, incorporation of more clinical endpoints allowed us to 
make statistical inferences based on a larger data pool.  A statistical advantage of modeling multiple 
events is the potential to add power to the analysis, which is particularly useful when modeling very rare 
outcomes or multiple recurrences of a single event type.  Despite the apparent advantages, statistical 
methods for analyzing multiple events data are underutilized in clinical research.  A likely explanation is 
that these are computationally intensive procedures that, until recently, were not widely supported by 
statistical software.   
 GEE models, on the other hand, are commonly used in clinical trials to analyze longitudinal or 
repeated measures data and, to a lesser extent, in multicenter trials when there is reason to believe that 
clinical outcomes may be related to the clinical center where treatment was administered.  Whereas the 
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advantage of multiple events models have to do with increased efficiency and being able to examine the 
data in a new way, application of GEE models has to do with selecting the appropriate inferential 
procedure for the data at hand.  Exploratory analysis of the BARI 2D cohort revealed substantial variation 
across clinical sites in selection of revascularization strategy and varying degrees of correlation within 
sites.  As a result, GEE modeling was used to account for clustering in our data in order to obtain more 
accurate estimates for our patient-level outcome of interest.  Failure to address this violation of 
independent observations would have resulted in underestimated standard errors, and thus, artificially low 
p-values and narrow confidence intervals, which may have led us to erroneously conclude that some 
relationships were statistically significant when in fact, they were not.  This may be more than a minor 
technical issue in the field of interventional cardiology where fast-paced innovations necessitate continual 
re-evaluation of treatments, and in some instances, require practice guidelines to be updated in order to 
reflect the best available evidence.  In this context, a series of reports committing a type I error as a result 
of inappropriate statistical analyses could have severe consequences.   
6.4 RELEVANCE OF BARI RESULTS IN THE CURRENT ERA 
Since BARI participants underwent initial treatment more than a decade ago according to the medical 
standards of that time, it is possible that recent advances in therapy (introduction of drug-eluting stents, in 
particular) may limit the generalizeability of BARI results to current practice.  Reports from randomized 
trials of bare metal stents79, 80 and drug-eluting stents81, 82 have demonstrated superiority of intracoronary 
stents over conventional balloon angioplasty in drastically lowering the incidence of restenosis.  Since 
restenosis is a time-related phenomenon that is limited to the early follow-up period, there is little reason 
to believe that our results on the long-term need for additional revascularizations, which is driven by 
progression of native disease, would be greatly altered by innovations in PCI.  Additionally, 
contemporary and conventional PCIs have not been shown to have a significantly different effect on 
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mortality or MI, which suggests that our findings regarding specific causes of death may also be relevant 
in the current era.   
6.5 ROLE OF BARI AND BARI 2D IN CORONARY INTERVENTION TRIALS 
Randomized clinical trials and registries have provided extensive evidence regarding the effectiveness 
and preferred method of coronary revascularization in specified patient subgroups.  The invaluable and 
unique contribution of BARI, in this broader context, was in establishing the role of diabetes in efficacy 
of revascularization treatment and atherosclerotic disease progression.  BARI has been instrumental in 
identifying diabetic patients as a ‘special’ population who are not only higher-risk but also different in 
terms of disease mechanism and response to treatment.  BARI 2D builds on these lessons learned from 
BARI and brings it into contemporary practice by incorporating new technologies and intensive 
modification of cardiovascular risk factors.   
 The BARI and BARI 2D trials represent a body of research encompassing over 20 years, and as 
such, evaluation of these cohorts provided a unique opportunity to investigate and address a variety of 
issues.  As medical innovations continue to increase longevity, long-term outcomes are of great interest in 
coronary intervention studies.  With over 10 years of follow-up, a major strength of BARI is the richness 
of the data which provide opportunities to dig deep into statistical analyses.  However, evolution of 
coronary revascularization devices and techniques in the last decade naturally bring to question the 
relevance of BARI results to current clinical practice.  Evidence to date suggests that contemporary and 
conventional percutaneous interventions do not differ with respect to death and MI, but to what extent 
innovations in PCI will challenge BARI results in the long run remains to be seen.  Despite promising 
short-term results, use of drug-eluting stents and Gp IIb/IIIa are currently lacking in long-term outcomes 
data, and efficacy has yet to be determined from randomized trials which are still ongoing.  In the 
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meantime, what factors should guide patient care?  These are some of the important issues and questions 
that will continue to be addressed by BARI 2D and other coronary intervention trials in the future. 
6.6 PUBLIC HEALTH SIGNIFICANCE 
Diabetes has rapidly evolved into a major public health concern.  Our findings in the BARI cohort support 
previous reports of a significantly worse prognosis in diabetic patients following myocardial 
revascularization.  Even after statistically adjusting for other confounding factors, the detrimental impact 
of diabetes on mortality as well as need for multiple repeat revascularizations was apparent.  These results 
underscore the importance of aggressive modification of CVD risk factors, especially glycemic control, to 
slow down the progression of atherosclerosis, which will be critical to long-term success in the diabetic 
population.  Given the enormous scope of diabetes and CVD, even very modest improvements in clinical 
outcomes may translate into significant gains from a public health perspective.   
 For the population at large, coronary interventions are safer and more effective than ever before, 
and continued progress in tertiary care will be critical to maintaining the gains that have been made.  
However, there is an irony in the way in which the medical advances that help extend the lives of 
individuals with ischemic heart disease (which represents a decrease in disease burden) simultaneously 
create generations living longer with this chronic and debilitating disease (which represents an increase in 
burden).  This ‘shift’ in the burden of CVD brings us back to the importance of disease prevention.  The 
alarming rise in recent years in the incidence of diabetes, obesity, and other unattended risk factors in 
younger generations are a stark reflection of lagging public health efforts in the primary and secondary 
prevention of CVD. 
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6.7 FUTURE RESEARCH 
Our findings bring to light several areas that warrant further research.  There is a great need to find cost-
effective approach to slowing down atherosclerotic disease progression, particularly in patients with 
diabetes.  The BARI 2D and FREEDOM trials will help elucidate the optimal CAD treatment strategy in 
the diabetes population.  By incorporating the latest technology and adjunctive therapies, these trials will 
provide invaluable information regarding whether, and to what extent, these improvements benefit 
patients with diabetes in the long-term, as these data will help guide clinical practice and future research.  
Since the number of studies dedicated to examining CAD in the diabetes population is very limited, much 
could be gained by encouraging future clinical and epidemiological studies to pre-specify an adequate 
number of participants with diabetes to allow for sufficiently powered subgroup analyses. 
 Improved management of cardiovascular risk factors in recent decades has led to marked declines 
in cardiac mortality in the general population but not in the diabetes subset, who bear a significantly 
greater CVD burden.  In previous studies, aggressive medical management including strict glucose 
control,83 angiotensin-converting enzyme (ACE) inhibitors,84 beta-blockers,85 and aspirin84, 85 has been 
associated with significantly improved long-term survival following acute MI in patients with diabetes.  
In fact, use of ACE inhibitors was shown to be even more effective in diabetic versus non-diabetic 
patients.84  These data suggest that failure to apply proven therapies may explain, at least in part, why the 
diabetic population has not benefited from the reduction in coronary deaths observed in the population at 
large.  Further research is needed to better understand why this has been the case.    
 Lastly, application of contemporary statistical methods that maximally utilize existing data can 
offer new insights into disease processes.  Compared to recommendations that require collection of new 
data, this recommendation is cost-effective, can be easily and readily implemented, and potentially lead to 
important findings.  An increasing availability of user-friendly statistical software that supports these 
computationally-intensive methods will likely encourage wider application of these procedures in clinical 
research.  
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 Table A6.1  Cumulative number of subsequent procedures over 10 years of follow-up 
 
1236 Procedures 
Included
in Analysis  
309 Procedures  
Not Included
in Analysis
Number of 
Repeat 
Procedures
No. of 
Patients  
(N=1606)
Cum. 
Percent
Cum. 
Number of 
Procedures
Cum. 
Percent
0 693 43% 0 0%
1 541 77% 541 35%
2 223 91% 987 64%
3 83 96% 1236 80%
4 32 98% 1364 88%
5 18 99% 1454 94%
6 7 99% 1496 97%
7 2 <100% 1510 98%
8 4 <100% 1542 <100%
9 0 <100% 1542 <100%
10 1 <100% 1543 <100%
11 1 <100% 1544 <100%
12 1 100% 1545 100%
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 Table A6.2  Comparison of PWP model estimates in the overall cohort and lower risk subgroup 
 
RR P-value RR P-value
1 1.44 <0.001 1.57 <0.001
2 1.00 0.97 1.08 0.64
3 0.64 0.01 0.54 0.01
Diabetes 1.43 <0.001 1.74 <0.001
Renal Dysfunction 1.75 <0.001 4.01 <0.01
Age ≥ 65 Years 0.84 <0.01 0.93 0.31
1 0.71 <0.001 0.68 <0.001
2 and 3 0.96 0.63 1.05 0.69
ST Elevation 0.52 <0.001 0.54 0.01
Unstable Angina 1.15 0.01 1.12 0.07
1 1.24 <0.01 1.25 0.01
2 and 3 0.95 0.58 0.90 0.31
Diffuse Lesions 1.13 0.03 1.15 0.05
1 1.13 0.07 1.17 0.05
2 and 3 0.86 0.09 0.83 0.07
*  Patients with propensity scores in the lower 70th percentile were considered to have a lower 
predicted probability of death.  Unadjusted 10-year mortality rates were 26% in the overall 
cohort and 16% in the lower risk strata; repeat revascularization rates in these groups were 42% 
and 41%, respectively.  
Male Gender
Smoking History
Proximal LAD Disease
Incomplete Revascularization
Repeat Revasc. 
Event Number
All Patients 
(N=1606)
Lower Risk* 
(n=1124)
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 w/ CABG:  20.7% vs 13.9%, p<0.01
Men
(n=1174)
None
(n=475)
None
(n=415)
2ND RR
(n=284)
1ST RR
(n=699)
PTCA
(n=456)
CABG
(n=243)
None
(n=181)
3RD RR
(n=103)
PTCA
(n=179)
CABG
(n=105)
*  Percentages are among patients who had a prior repeat revascularization event within each strata
Women
(n=432)
None
(n=218)
None
(n=126)
2ND RR
(n=88)
1ST RR
(n=214)
CABG
(n=60)
PTCA
(n=154)
None
(n=42)
3RD RR
(n=46)
CABG
(n=30)
PTCA
(n=58)
1ST REPEAT REVASC
60% vs 50%, p<0.01
2ND REPEAT REVASC*
41% vs 41%, p=0.90
3RD REPEAT REVASC*
36% vs 52%, p<0.01
w/ CABG:  15.0% vs 14.0%, p=0.88
 
Figure A6.1  Comparison of repeat revascularization strategies by gender
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 w/CABG:  21.3% vs 17.5%, p=0.04
Proximal LAD +
(n=573)
None
(n=225)
None
(n=211)
2ND RR
(n=137)
1ST RR
(n=348)
PTCA
(n=226)
CABG
(n=122)
None
(n=88)
3RD RR
(n=49)
PTCA
(n=90)
CABG
(n=47)
Proximal LAD -
(n=1033)
None
(n=468)
None
(n=330)
2ND RR
(n=235)
1ST RR
(n=565)
CABG
(n=181)
PTCA
(n=384)
None
(n=135)
3RD RR
(n=100)
CABG
(n=88)
PTCA
(n=147)
1ST REPEAT REVASC
61% vs 55%, p=0.02
2ND REPEAT REVASC*
39% vs 42%, p=0.51
3RD REPEAT REVASC*
36% vs 43%, p=0.20
w/CABG:  13.5% vs 15.6%, p=0.67
*  Percentages are among patients who had a prior repeat revascularization event within each strata
 
Figure A6.2  Comparison of repeat revascularization strategies by proximal LAD disease status 
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 w/ CABG:  23.0% vs 12.2%, p<0.01
IR +
(n=991)
None
(n=413)
None
(n=354)
2ND RR
(n=224)
1ST RR
(n=578)
PTCA
(n=350)
CABG
(n=228)
None
(n=136)
3RD RR
(n=88)
PTCA
(n=135)
CABG
(n=89)
IR -
(n=615)
None
(n=280)
None
(n=187)
2ND RR
(n=148)
1ST RR
(n=335)
CABG
(n=75)
PTCA
(n=260)
None
(n=87)
3RD RR
(n=61)
CABG
(n=46)
PTCA
(n=102)
1ST REPEAT REVASC
58% vs 54%, p=0.13
2ND REPEAT REVASC*
39% vs 44%, p=0.11
3RD REPEAT REVASC*
39% vs 41%, p=0.71
w/ CABG:  15.4% vs 13.7%, p=0.06
*  Percentages are among patients who had a prior repeat revascularization event within each strata
 
Figure A6.3  Comparison of repeat revascularization strategies by incomplete revascularization 
(IR) status 
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